Podcasts about celera

Recibimos en este espacio Alejandro Rodríguez Bolaños, director de Celera; yManuel Esbrí Ramos, Co-fundador de Simbionte y miembro de Celera. Como siempre con Julio Rodríguez, fundador y CEO de la Red de Mentoring de España.

Recibimos en este espacio Alejandro Rodríguez Bolaños, director de Celera; yManuel Esbrí Ramos, Co-fundador de Simbionte y miembro de Celera. Como siempre con Julio Rodríguez, fundador y CEO de la Red de Mentoring de España.

Recibimos en este espacio Alejandro Rodríguez Bolaños, director de Celera; yManuel Esbrí Ramos, Co-fundador de Simbionte y miembro de Celera. Como siempre con Julio Rodríguez, fundador y CEO de la Red de Mentoring de España.

La sede de Afundación acogió el pasado martes el acto de entrega de los premios Líderes de Futuro, otorgados por el Rotary Club Ferrol. Alejandro Permuy, el presidente, señala que el galardón creado por la entidad «pretende poner en valor a los jóvenes de nuestra zona». El ganador de esta cuarta edición fue Manuel Rico Fernández San Silvestre (Ferrol, 2001), un joven ferrolano de 22 años estudiante de Medicina, con una brillante trayectoria a pesar de su juventud. Y es que Manuel estudia el grado de Medicina en la Universidad de Santiago de Compostela y ha estado becado en Luisiana y Harvard en los últimos años. Pasó también en 2023 por la Charité-Universitätsmedizin de Berlín, a través del programa Erasmus. Además, recientemente, se ha convertido en el más joven de los seleccionados en el programa Celera, un programa creado por el científico Javier García Martínez y la Fundación Rafael del Pino, que identifica a jóvenes con talento excepcional para dotarlos de herramientas que potencien sus capacidades profesionales y personales. Esto representa para él una gran oportunidad para seguir desarrollándose en el campo de la investigación, y más concretamente de las enfermedades neurodegenerativas. Especialmente el párkinson, porque, explica, le toca en la familia. Los premios Líderes del Futuro distinguieron también con accésits al piragüista Martín López y a Marta Canosa, palista del club Copacabana de Ferrol de Kayak Polo. La entrega de los galardones estuvo amenizada y presentada por el joven ilusionista Magic Mateo.

How about some analog design to start off your Friday? Celera CEO Pat Brockett and Celera COO Alberto Viviani join me this week to discuss the challenges of automating analog design, why there is a widespread need for custom analog chips, and how Celera is dramatically changing the face of analog chip design. Also this week, I investigate new sound-powered sensors and how these passive sound-sensitive sensors could save millions of batteries from landfills.  

J. Craig Venter, PhD, ( https://www.jcvi.org/about/j-craig-venter ) is regarded as one of the leading scientists of the 21st century for his numerous invaluable contributions to genomic research. Dr. Venter is founder, chairman, and CEO of the J. Craig Venter Institute (JCVI), a not-for-profit, research organization with approximately 120 scientists and staff dedicated to human, microbial, synthetic, and environmental genomic research, and the exploration of social and ethical issues in genomics. Dr. Venter began his formal education after a tour of duty as a Navy Corpsman in Vietnam from 1967 to 1968. After earning both a Bachelor of Science in biochemistry and a PhD in physiology and pharmacology from the University of California at San Diego, he was appointed professor at the State University of New York at Buffalo and the Roswell Park Cancer Institute. In 1984, he moved to the National Institutes of Health campus where he developed expressed sequence tags or ESTs, a revolutionary new strategy for rapid gene discovery. In 1992, Dr. Venter founded The Institute for Genomic Research (TIGR, now part of JCVI), a not-for-profit research institute, where in 1995 he and his team decoded the genome of the first free-living organism, the bacterium Haemophilus influenzae, using the new whole genome shotgun technique. In 1998, Dr. Venter founded Celera Genomics to sequence the human genome using new tools and techniques he and his team developed. This research culminated with the February 2001 publication of the human genome in the journal, Science. He and his team at Celera also sequenced the fruit fly, mouse, and rat genomes. Dr. Venter and his team at JCVI continue to blaze new trails in genomics. They have sequenced and analyzed hundreds of genomes, and have published numerous important papers covering such areas as environmental genomics, the first complete diploid human genome, and the groundbreaking advance in constructing the first self-replicating bacterial cell using synthetic DNA. Dr. Venter is one of the most frequently cited scientists, and the author of more than 280 research articles. He is also the recipient of numerous honorary degrees, public honors, and scientific awards, including the 2008 United States National Medal of Science, the 2002 Gairdner Foundation International Award, the 2001 Paul Ehrlich and Ludwig Darmstaedter Prize, and the King Faisal International Award for Science. Dr. Venter is a member of numerous prestigious scientific organizations including the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the American Society for Microbiology. Dr. Venter is also a serial entrepreneur who has co-founded several companies including Synthetic Genomics, Inc., now Viridos and Human Longevity, Inc. (HLI). Dr. Venter's newest book "The Voyage of Sorcerer II: The Expedition That Unlocked the Secrets of the Ocean's Microbiome" was recently released on September 12, 2023 - https://www.amazon.com/Voyage-Sorcerer-II-Expedition-Microbiome/dp/0674246470 Support the show

A mozdonyok csodálóinak bemutatjuk a Nohab-ot Tudás.hu     2023-07-17 05:55:59     Infotech Üzemanyag Menetrend Dízel Mekkora rajongás övezhet egy mozdonyt? Miképp vehetett „nyugati” mozdonyt a szocialista Magyarország, és miért csak húszat? Hogyan lehet, hogy több, mint két évtizeddel a menetrendszerű szolgálat vége után is találkozhatunk a 60 éve szolgálatba állt dízelmozdonyokkal? Ha azt mondjuk NOHAB, akkor a magyar vasútrajongók egy emberként sóhajtanak fel. Bíróság előtt a tinik, akik meghackelték a fél világot PCWorld     2023-07-17 06:07:26     Infotech Bíróság Hacker Egy 18 és egy 17 éves srác kulcsszerepet játszott a rettegett Lapsus hackercsoport akcióiban. Elszabadultak az „anydeskes” csalók Mínuszos     2023-07-17 07:33:25     Infotech Rendőrség Bűnözők húszmillió forintot csaltak ki egy embertől azzal, hogy rávették, telepítsen a számítógépére egy programot, amelynek segítségével megszerezték a bankoláshoz használt adatait. A rendőrség azonosította és június végén elfogta az elkövetőket. Oláh-Paulon László alezredes, az Országos Rendőr-főkapitányság bűnmegelőzési osztályának vezetője az o Miért tűntek öregebbnek az emberek a múltban? 24.hu     2023-07-17 14:19:28     Tudomány Erősen hozzájárul az ember fiatalodásához az egészségügy fejlődése és az életmódban eszközölt változás is. Tűzijáték helyett több mint ezer drón fényjátéka díszítette az eget Texasban Rakéta     2023-07-17 11:25:00     Infotech USA Drón Petárda Tűzijáték Texas LED A Sky Elements Drone Shows nevű vállalat 1002 darab drón összehangolt mozgásával végrehajtott 10 perces bemutatójával ünnepelte az amerikai függetlenség napját Texasban. A LED-ekkel felszerelt többrotoros eszköz látványos koreográfiája az amerikai történelem legfontosabb momentumait és az Egyesült Államok nemzeti jelképeit rajzolta az égre, ezzel b Térerőt ad a rejtélyes repülő 20 kilométer magasról First Class     2023-07-17 11:57:37     Tudomány Repülőgép Drón Műhold Műholdak alternatívája is lehet a kísérleti drón, ami a várakozások szerint képes lesz egy évet is eltölteni 20 kilométeres magasságban, leszállás nélkül. Negatív cash-flow és menekülő hirdetők jellemzik a Twitter első fél évét Bitport     2023-07-17 13:18:00     Infotech Twitter Elon Musk Tavasszal Elon Musk még egyensúlyban lévő bevételekről és kiadásokról, főként pedig visszatérő hirdetőkről beszélt, de egy picit elsiette a dolgot. Az ABB és a Microsoft együttműködik, hogy a generatív mesterséges intelligenciát használják az ipari alkalmazásokban Márkamonitor     2023-07-17 10:36:09     Infotech Mesterséges intelligencia Microsoft OpenAI ABB Az Abb és a Microsoft tovább bővíti a két vállalat között régóta fennálló partnerséget. Legújabb együttműködésük célja, hogy az Azure OpenAi Service-t integrálják az Abb Ability™ Genix ipari analitikai és Mi-programcsomagba. A két vállalat majd együtt dolgozik a generatív Mi-technológia bevezetésének megvalósításán, hogy az ipari ügyfeleknek segíts Nagyon vigyázzon: meggyőző csalás terjed a Magyar Posta nevében, mutatjuk, mikre figyeljen, hogy ne lophassák el a pénzét hvg.hu     2023-07-17 07:02:00     Infotech Magyar Posta Zrt. Könnyen be lehet dőlni a legújabb, a Magyar Posta nevében terjedő csalásnak, ha külföldről várunk csomagot: érdemes figyelni a részletekre, mert első látásra minden nagyon hitelesnek tűnhet. Egyre gyakoribbak a tengerparti cápatámadások, ez lehet az oka Mandiner     2023-07-17 06:22:51     Tudomány Az elmúlt 22 évben 500 cápatámadás ért embert, és ezek 25 százalékban halálos kimenetelűek voltak. Új robotikai motorplatform-sorozatot jelentett be a Celera okosipar.hu     2023-07-17 05:06:30     Infotech Cégvilág Robot A Celera Motion a korábbi, közvetlen meghajtású motorplatformjainak új, legnagyobb változatát alkotta meg Omni+ néven, ami a 60,70 és 100 után 130 milliméteres méretével a sorozat legnagyobb közvetlen meghajtású, keret nélküli modellje. A gyártó a tőle várható legnagyobb nyomatéki sűrűséget kínálja, rendkívül alacsony cogginggal, alacsony profillal Magyar társalapítóval indította el az új cégét Elon Musk Haszon.hu     2023-07-17 09:54:10     Cégvilág Csongrád-Csanád Szeged Mesterséges intelligencia Google Elon Musk xAI Új, mesterséges intelligenciával foglalkozó vállalat alapítását jelentette be Elon Musk. A cég egyik társalapítója magyar. A jelentős nemzetközi tapasztalatokkal bíró Christian Szegedy az alkalmazott matematika doktora. Korábban például a Google-nek is dolgozott. Új cég indítását jelentett be Elon Musk xAI néven új, mesterséges intelligenciá AI segítségével csökkentik az üzemanyagtartályok zaját newtechnology.hu     2023-07-17 05:33:51     Cégvilág Üzemanyag Tankolás Mesterséges intelligencia A mesterséges intelligencia számos tervezési és mérnöki munkafolyamatot javíthat fel. Különösen hasznos ez az autóiparban, ahol az elektrifikáció és az önvezetés előretörésével a gyártók forradalmi technológiákkal kezdenek dolgozni. Az új elvárások tervezési kihívásokkal szembesítik a vállalatokat, de az AI-megoldások különösen értékesnek bizonyuln

A mozdonyok csodálóinak bemutatjuk a Nohab-ot Tudás.hu     2023-07-17 05:55:59     Infotech Üzemanyag Menetrend Dízel Mekkora rajongás övezhet egy mozdonyt? Miképp vehetett „nyugati” mozdonyt a szocialista Magyarország, és miért csak húszat? Hogyan lehet, hogy több, mint két évtizeddel a menetrendszerű szolgálat vége után is találkozhatunk a 60 éve szolgálatba állt dízelmozdonyokkal? Ha azt mondjuk NOHAB, akkor a magyar vasútrajongók egy emberként sóhajtanak fel. Bíróság előtt a tinik, akik meghackelték a fél világot PCWorld     2023-07-17 06:07:26     Infotech Bíróság Hacker Egy 18 és egy 17 éves srác kulcsszerepet játszott a rettegett Lapsus hackercsoport akcióiban. Elszabadultak az „anydeskes” csalók Mínuszos     2023-07-17 07:33:25     Infotech Rendőrség Bűnözők húszmillió forintot csaltak ki egy embertől azzal, hogy rávették, telepítsen a számítógépére egy programot, amelynek segítségével megszerezték a bankoláshoz használt adatait. A rendőrség azonosította és június végén elfogta az elkövetőket. Oláh-Paulon László alezredes, az Országos Rendőr-főkapitányság bűnmegelőzési osztályának vezetője az o Miért tűntek öregebbnek az emberek a múltban? 24.hu     2023-07-17 14:19:28     Tudomány Erősen hozzájárul az ember fiatalodásához az egészségügy fejlődése és az életmódban eszközölt változás is. Tűzijáték helyett több mint ezer drón fényjátéka díszítette az eget Texasban Rakéta     2023-07-17 11:25:00     Infotech USA Drón Petárda Tűzijáték Texas LED A Sky Elements Drone Shows nevű vállalat 1002 darab drón összehangolt mozgásával végrehajtott 10 perces bemutatójával ünnepelte az amerikai függetlenség napját Texasban. A LED-ekkel felszerelt többrotoros eszköz látványos koreográfiája az amerikai történelem legfontosabb momentumait és az Egyesült Államok nemzeti jelképeit rajzolta az égre, ezzel b Térerőt ad a rejtélyes repülő 20 kilométer magasról First Class     2023-07-17 11:57:37     Tudomány Repülőgép Drón Műhold Műholdak alternatívája is lehet a kísérleti drón, ami a várakozások szerint képes lesz egy évet is eltölteni 20 kilométeres magasságban, leszállás nélkül. Negatív cash-flow és menekülő hirdetők jellemzik a Twitter első fél évét Bitport     2023-07-17 13:18:00     Infotech Twitter Elon Musk Tavasszal Elon Musk még egyensúlyban lévő bevételekről és kiadásokról, főként pedig visszatérő hirdetőkről beszélt, de egy picit elsiette a dolgot. Az ABB és a Microsoft együttműködik, hogy a generatív mesterséges intelligenciát használják az ipari alkalmazásokban Márkamonitor     2023-07-17 10:36:09     Infotech Mesterséges intelligencia Microsoft OpenAI ABB Az Abb és a Microsoft tovább bővíti a két vállalat között régóta fennálló partnerséget. Legújabb együttműködésük célja, hogy az Azure OpenAi Service-t integrálják az Abb Ability™ Genix ipari analitikai és Mi-programcsomagba. A két vállalat majd együtt dolgozik a generatív Mi-technológia bevezetésének megvalósításán, hogy az ipari ügyfeleknek segíts Nagyon vigyázzon: meggyőző csalás terjed a Magyar Posta nevében, mutatjuk, mikre figyeljen, hogy ne lophassák el a pénzét hvg.hu     2023-07-17 07:02:00     Infotech Magyar Posta Zrt. Könnyen be lehet dőlni a legújabb, a Magyar Posta nevében terjedő csalásnak, ha külföldről várunk csomagot: érdemes figyelni a részletekre, mert első látásra minden nagyon hitelesnek tűnhet. Egyre gyakoribbak a tengerparti cápatámadások, ez lehet az oka Mandiner     2023-07-17 06:22:51     Tudomány Az elmúlt 22 évben 500 cápatámadás ért embert, és ezek 25 százalékban halálos kimenetelűek voltak. Új robotikai motorplatform-sorozatot jelentett be a Celera okosipar.hu     2023-07-17 05:06:30     Infotech Cégvilág Robot A Celera Motion a korábbi, közvetlen meghajtású motorplatformjainak új, legnagyobb változatát alkotta meg Omni+ néven, ami a 60,70 és 100 után 130 milliméteres méretével a sorozat legnagyobb közvetlen meghajtású, keret nélküli modellje. A gyártó a tőle várható legnagyobb nyomatéki sűrűséget kínálja, rendkívül alacsony cogginggal, alacsony profillal Magyar társalapítóval indította el az új cégét Elon Musk Haszon.hu     2023-07-17 09:54:10     Cégvilág Csongrád-Csanád Szeged Mesterséges intelligencia Google Elon Musk xAI Új, mesterséges intelligenciával foglalkozó vállalat alapítását jelentette be Elon Musk. A cég egyik társalapítója magyar. A jelentős nemzetközi tapasztalatokkal bíró Christian Szegedy az alkalmazott matematika doktora. Korábban például a Google-nek is dolgozott. Új cég indítását jelentett be Elon Musk xAI néven új, mesterséges intelligenciá AI segítségével csökkentik az üzemanyagtartályok zaját newtechnology.hu     2023-07-17 05:33:51     Cégvilág Üzemanyag Tankolás Mesterséges intelligencia A mesterséges intelligencia számos tervezési és mérnöki munkafolyamatot javíthat fel. Különösen hasznos ez az autóiparban, ahol az elektrifikáció és az önvezetés előretörésével a gyártók forradalmi technológiákkal kezdenek dolgozni. Az új elvárások tervezési kihívásokkal szembesítik a vállalatokat, de az AI-megoldások különösen értékesnek bizonyuln

Matt Sitter is an experienced Project Manager at McChrystal Group, and has led two client engagements with global technology companies. In his role as manager of client engagements, Matt has advised senior leadership to improve internal communications and build organizational alignment. Matt joined McChrystal Group following a successful career in the healthcare industry, serving in management positions in multiple functional areas. Matt worked as the Product Marketing Manager for Elekta AB, the Director of Disease Management for Celera, Inc., and the Director of Reimbursement Analytics for Veracyte. In each of these positions, Matt utilized and personally developed new methodology, metrics, and analytics – demonstrating his innovative approach to project management. Matt completed his undergraduate studies at Brown University and received his MBA from Dartmouth College's Tuck School of Business.

Sindy obtained a B.S. Degree in Kinesiology and Physical Education from California State University, East Bay.  In her junior year, she started, teaching Dance.  Later, she taught high school and pivoted into a Trainer role at a youth job-training program combining her love of education and business. In an HR career spanning over 25 years, she found her niche in a recruiting.  She has been a Recruiter, Sr. Recruiter, Recruiting Manager, Director of Talent Acquisition, and Principal Recruiting Consultant.   Sindy's has worked in various industries, including healthcare and information technology; manufacturing like Clorox and Mother's Cookies; as well as smaller bio-techs and pharmaceutical companies like Amgen; Berkeley Heart Lab, Inc., a Celera business; and Global Blood Therapeutics, Inc., a division of Pfizer. Sindy is the Founder, Host of, the Insider's Career Club, a career podcast, career coaching business, and website. In this episode, Sindy shared so many great ideas on how to find your next great job easier and faster, including:·         What are the four types of recruiters an applicant might run into, and what should you know about working with them?·         How can you prepare for a virtual interview to be more effective?·         Why do you want to write down your accomplishments, and what should you do with them?·         What does it mean when people say, “Rejection is a part of the job search process”?·         Why is being honest and knowing your skills critical in interviewing?Sindy was so giving of her expertise and insights in the recruiting area.  You will want to listen to this episode more than once to ensure you get all the tips and techniques she shared.   These tip sheets can be found @insiderscareerclub.com under job search.Contact Sindy:Email: sindythomas99@gmail.com; www.linkedin.com/in/sindythomas/ or at www.insiderscareerclub.com

¿Te imaginas conseguir levantar 1 millón gastándote solo 7 dólares en un hosting? ¿Te imaginas ser capaz de diseñar y lanzar un software en tan solo 11 días?Así fueron los inicios de Capchase, una startup épica que en tan solo dos años y medio de vida ha crecido un 350% y ha levantado 900 millones para prestar dinero a los mejores SaaS.Pero hay algo incluso más sorprendente; y es que esta verdadera hazaña la han llevado a cabo un equipo de founders que aún no han cumplido la treintena. Hoy tenemos a uno de ellos, Ignacio Moreno, que conoció al resto de sus futuros socios cuando entró de becario en otra startup patria: Geoblink. El talento llama al talento.Así es cómo se entiende su modelo de financiación con deuda para que no te diluyas, cómo hicieron un “mago de Oz” con su software y cómo se gestiona a un equipo en 3 países diferentes.Puedes encontrarnos en cualquier canal y plataforma:Web

Why did Scott Bores Drop Out Of Instrument Training?Should Scott Go Back An Take His IFR Checkride?Pelee Island Ferry ScheduleOwning vs. Chartering Airplaneshttps://ottoaviation.com/If you would prefer watching the full episode instead of just listening, here is the link: https://rumble.com/v2899y2-127-what-is-an-instrument-rating-why-learn-ifr-ga-limitations-guest-jeff-da.htmlA short video clip of the Celera 500 conversation from this episode is available here: https://www.youtube.com/watch?v=kFV9abU0lwUSubscribe And Watch Full Episodes On The Rumble: https://rumble.com/c/FARAIMSubscribe And Watch Highlight Clips On The YouTube: https://www.youtube.com/c/FARAIMPodcastFollow On The Twitter: https://twitter.com/faraimpodcastConsider Joining The Ground Crew To Support The Show: https://club.pilotground.com/checkout/ground-crew

SHOW NOTES 01:50 The first perovskite solar cell with a commercially viable lifetime is here | Interesting Engineering  A team of researchers from Princeton University has built the first perovskite solar cells that last long enough to be commercially viable.Silicon-based cells, which many regard as an expensive and suboptimal component, have dominated the renewable energy market since their introduction in 1954. This new technology, which is not only incredibly durable but also meets common efficiency standards, has the potential to change that. Expected to outperform industry norms for roughly 30 years, well beyond the 20-year criterion for solar cell viability Perovskite solar cells are regarded as high-efficiency, low-cost modular technology for implementation in the renewable power industry. Less Energy = Less $$$ Would become more fragile in that case The name “perovskite” comes from the nickname for their crystal structure. Can be manufactured at room temperature, which means they need less energy than manufacturing silicon.  Can be modified to be flexible and transparent The new device created by these researchers estimated lifetime is a five-fold increase over the previous record, which was established by a lower efficiency perovskite solar cell in 2017. Additionally they created a new testing method allowing them to test the longevity of these particular types of solar cells. Ranging from a regular summer day's baseline temperature to an extreme of 230 degrees Fahrenheit (110 degrees Celsius). “accelerated aging technique” Chose four aging temperatures and measured outcomes over four independent data streams. Overall, they found that the device will run at or above 80 percent of its peak efficiency under continuous illumination for at least five years.According to the researchers, that is the equivalent of 30 years of outdoor operation in a city like Princeton, New Jersey.  Joseph Berry, a senior fellow at the National Renewable Energy Laboratory who was not involved in the study, said:“This paper is likely going to be a prototype for anyone looking to analyze performance at the intersection of efficiency and stability … By producing a prototype to study stability, and showing what can be extrapolated [through accelerated testing], it's doing the work everyone wants to see before we start field testing at scale. It allows you to project in a way that's really impressive."   07:36 Immunotherapy booster produces 10,000 times more cancer-fighting cells | New Atlas Researchers at Washington University in St. Louis have found that adding a booster protein can significantly improve the outcome of cancer immunotherapy.The research showed the protein produced 10,000 times more immune cells in mice, and all mice survived the entire experiment. We are talking about  CAR T cell immunotherapy, which is a promising new treatment where doctors extract T cells from a patient, genetically engineer them to target specific cancer cells, and return them to the body to hunt those cells down.  The effectiveness can start to drop over time. In the new study, the scientists investigated ways to combat this problem by boosting the number of T cells. Doesn't naturally stick around very long, so the researchers modified it to circulate in the body for weeks. They turned to a protein called interleukin-7 (IL-7), which the body naturally expresses to ramp up T cell production in the event of illness. The team tested this longer-lasting IL-7 in mouse models of lymphoma, administering the protein on various days after the initial CAR T cell injection.3 groups: 1.) Control (no immunotherapy), 2.) Received CAR T cell therapy without IL-7, and 3.) with IL-7 John DiPersio, senior author of the study, talks on the findings:“When we give a long-acting type of IL-7 to tumor-bearing immunodeficient mice soon after CAR T cell treatment, we see a dramatic expansion of these CAR-T cells greater than ten-thousandfold compared to mice not receiving IL-7 … These CAR T cells also persist longer and show dramatically increased anti-tumor activity.” Every mouse that received CAR T cell therapy and IL-7 survived the entire 175 days of the experiment, with their tumors shrinking to the point of being undetectable by day 35. In contrast, mice that received immunotherapy alone survived just 30 days on average. Human clinical trials of IL-7-boosted CAR T cell therapy are set to begin soon in patients with a type of lymphoma.   12:29 Study identifies receptor that could alleviate need for chemo, radiation pre-T cell therapy | ScienceDaily   Before a patient can undergo T cell therapy designed to target cancerous tumors, the patient's entire immune system must be destroyed with chemotherapy or radiation.Reducing your immune cells helps the transferred T cells to be more effective.  Toxic Side Effects: nausea, extreme fatigue and hair loss. Now a research team ,a collaboration between scientists from UCLA, Stanford and the University of Pennsylvania, has shown that a synthetic IL-9 receptor allows those cancer-fighting T cells to do their work without the need for chemo or radiation. Christopher Garcia, PhD, at Stanford, talks on these T cells:“When T cells are signaling through the synthetic IL-9 receptor, they gain new functions that help them not only outcompete the existing immune system but also kill cancer cells more efficiently … I have a patient right now struggling through toxic chemotherapy just to wipe out his existing immune system so T cell therapy can have a fighting chance. But with this technology you might give T cell therapy without having to wipe out the immune system beforehand." Imagine being able to receive this treatment without destroying your whole body. The body would be in a much better position to fight off any other outside problem. Antoni Ribas, MD, PhD, a senior investigator on the study, believes this finding, “opens a door for us to be able to give T cells a lot like we give a blood transfusion." Back in 2018 a set of researchers found that a synthetic cell growth cytokine could be used to stimulate T cells engineered with a matching synthetic receptor. With this system, T cells can be manipulated even after they have been given to a patient. But they were looking at IL-2 back then, but now they started investigating IL-9. The synthetic IL-9 signal made T cells take on a unique mix of both stem-cell and killer-like qualities that made them more robust in fighting tumors. According to the researchers, "In one of our cancer models, we cured over half the mice that were treated with the synthetic IL-9 receptor T cells."Proved to be effective in multiple systems The process worked whether they gave the cytokine to the whole mouse or directly to the tumor   17:34 Astronomers Unveil The Most Detailed Map of The Metal Asteroid Psyche Yet | ScienceAlert  The asteroid Psyche is especially interesting, and NASA is sending a mission to investigate the unusual chunk of rock.In advance of that mission, a team of researchers combined observations of Psyche from an array of telescopes and constructed a map of the asteroid's surface. Psyche (16 Psyche) is an M-type asteroid, which is the rarest type of asteroid and makes up about 8 percent of known asteroids.Contain more metal than the other asteroid types, and scientists think they're the source of iron meteorites that fall to Earth. Called a dwarf planet because it's about 220 kilometers (140 mi) in diameter.  Psyche is sometimes called the 'Gold-mine asteroid' because of the wealth of iron and nickel it contains NASA wants to take a closer look at the asteroid.The mission is called Psyche and is scheduled for launch sometime in fall 2022.  The spacecraft will rely on solar-electric propulsion and a gravity-assist maneuver with Mars to arrive at Psyche in 2026. It'll spend 21 months studying the asteroid and will follow four separate orbital paths, each successive one closer than the previous. A team of researchers constructed a new map of Psyche's surface to help prepare for the mission.  Saverio Cambioni from MIT's Department of Earth said in a press release:“Psyche's surface is very heterogeneous … It's an evolved surface, and these maps confirm that metal-rich asteroids are interesting enigmatic worlds. It's another reason to look forward to the Psyche mission going to the asteroid." The new map is based on two types of measurements. Pure iron has an infinite dielectric constant.  One is thermal inertia, which is how long a material takes to reach the temperature of its environment. Higher thermal inertia means it takes longer. The second is the dielectric constant. The dielectric constant describes how well a material conducts heat, electricity, or sound. A material with a low dielectric constant conducts poorly and is a good insulator and vice versa. Combining thermal inertia and dielectric constant measurements gives a good idea of which surface regions on Psyche are rich in iron and other metals. Overall, the study shows that 16 Psyche's surface is covered in a large variety of materials. It also adds to other evidence showing that the asteroid is metal-rich, though the abundance of metals and silicates varies significantly in different regions.   22:39 World's most efficient passenger plane gets hydrogen powertrain | New Atlas  The Celera 500L is a remarkable design, and according to the company behind it, Otto Aviation, its odd shape delivers an astonishing 59 percent reduction in drag, and a massive leap in efficiency and range compared to traditional plane geometries. Otto claims the Celera 500L in standard fossil fuel-propelled form is "the most fuel-efficient, commercially viable business aircraft in the world."The whole thing is designed to maximize laminar flow – smooth layers of airflow with little to no mixing of adjacent layers moving at different speeds. Trying to avoid the swirls and eddies that lead to air turbulence at speed, causing aerodynamic drag and wasted energy. The company states that it uses 80 percent less fuel than a traditional design. Running on an efficient 550-horsepower combustion engine, Otto claims this thing will fly six passengers up to 4,500 nautical miles (8,334 km) at cruise speeds over 460 mph (740 km/h), challenging small business jets for top speed while more than doubling their range.A glide ratio of 22:1 allows pilots to switch off the engine altogether and glide for up to 120 miles (200 km) completely unpowered. Now the rich people who fly around in their CO2 producing private jets can make a change…will they? Otto has built a full-scale prototype, and by November last year the company announced it had completed some 55 successful test flights, reaching speeds over 250 mph (400 km/h) and altitudes up to 15,000 ft, and that "all test flights have validated the aircraft's operating performance goals." Otto has now announced a collaboration with hydrogen aviation pioneers ZeroAvia to develop a fuel cell-electric powertrain specific to the Celera's requirements.The shape works well with a hydrogen concept – hydrogen powertrains can weigh much less than battery-electric ones, but they tend to take up a bit of space. ZeroAvia is being relatively humble with its ambitions to begin with, aiming for a range of just 1,000 nautical miles (1,852 km) of zero-emissions range for a hydrogen-fueled Celera. Founder and CEO of ZeroAvia, Val Miftakhov, said in a press release:“The majority of our commercial deals to date have focused on retrofit and line-fit for existing airframes, which is essential to deliver zero-emission flight to market as quickly as possible. However, efficiency gains from new airframe design can expand the impact of zero-emission aviation. We are pleased to collaborate with innovators, like Otto Aviation, bringing cutting-edge clean sheet designs to market as we can optimize the hydrogen-electric propulsion system for those designs.” Otto has already shown it can complete successful flights of their fossil fuel plane, but we will wait and see how this partnership pans out.

Découvrez le troisième épisode de notre cycle sur le Projet Génome Humain. Dans ce podcast, nous évoquons la fin du projet et le résultat de la course entre le PGH et Celera, avant de faire un pas en arrière pour mesurer l'ampleur de la réussite du projet.

Why is hibernation something that bears and squirrels do, but humans don't? Even more interesting, what's going on inside a hibernating animal, on a physiological and genetic level, that allows them to survive the winter in a near-comatose state without freezing to death and without ingesting any food or water? And what can we learn about that process that might inform human medicine?Those are the big questions being investigated right now by a four-year-old startup in California called Fauna Bio. And Harry's guests today are two of Fauna Bio's three founding scientists: Ashley Zehnder and Linda Goodman. They explain how they got interested in hibernation as a possible model for how humans could protect themselves from disease, and how progress in comparative genomics over the last few years has made it possible to start to answer that question at the level of gene and protein interactions. The work is shedding light on a previously neglected area of animal behavior that could yield new insights for treating everything from neurodegenerative diseases to cancer.Please rate and review The Harry Glorikian Show on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:1. Open the Podcasts app on your iPhone, iPad, or Mac. 2. Navigate to The Harry Glorikian Show podcast. You can find it by searching for it or selecting it from your library. Just note that you'll have to go to the series page which shows all the episodes, not just the page for a single episode.3. Scroll down to find the subhead titled "Ratings & Reviews."4. Under one of the highlighted reviews, select "Write a Review."5. Next, select a star rating at the top — you have the option of choosing between one and five stars. 6. Using the text box at the top, write a title for your review. Then, in the lower text box, write your review. Your review can be up to 300 words long.7. Once you've finished, select "Send" or "Save" in the top-right corner. 8. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed next to any reviews you leave from here on out. 9. After selecting a nickname, tap OK. Your review may not be immediately visible.That's it! Thanks so much.TranscriptHarry Glorikian: Hello. I'm Harry Glorikian, and this is The Harry Glorikian Show, where we explore how technology is changing everything we know about healthcare.It's April and spring is well underway, even though it's been a pretty cold one so far here in New England.It's the kind of weather that makes you want to pull the covers over your head in the morning and just sleep in. Or maybe just hibernate like a bear until summer is really here.But when you think about it, what is hibernation? Why is it something that bears and squirrels do, but humans don't?Even more interesting, what's going on inside a hibernating animal, physiologically, that allows them to survive all winter without freezing to death and without ingesting any food or water?And what can we learn about that process that might inform human medicine?Those are the big questions being investigated right now by a four-year-old startup in California called Fauna BioAnd my guests today are two of Fauna Bio's three founding scientists: Ashley Zehnder and Linda Goodman. I asked them to explain how they got interested in hibernation as a possible model for how humans could protect themselves from disease.…And how progress in comparative genomics over the last few years has made it possible to start to answer that question at the level of gene and protein interactions.We've always looked to the natural world, especially the world of plants, for insights into biochemistry that could inspire new drugs. But what's exciting to me about Fauna Bio is that they're shining a light on a previously neglected area of animal behavior that could yield new insights for treating everything from neurodegenerative diseases to cancer.So, here's my conversation with Ashley Zehnder and Linda Goodman.Harry Glorikian: Ashley. Linda, welcome to the show.Ashley Zehnder: Thanks, Harry, we're excited to be here today. It's going to be fun.Linda Goodman: Yeah, thanks for having us.Harry Glorikian: Yeah, I mean, well, you guys are someplace sunny and warm, and I'm actually I shouldn't say that it's actually sunny right now on the East Coast. So I'm not I'm not.Linda Goodman: Don't jinx yourself.Harry Glorikian: But the temperature is going to drop. Like to I think they said 18. So everything will freeze tonight for sure. So it'll, you know, it's one of those days, but. I want to jump right into this because we've got a lot of ground to cover. Like there's so many questions that I have after sort of looking into the company and sort of digging in and, you know, but even before we jump into what you're working on. Right, I really want to talk about hibernation. Maybe because I'm jealous and I'd like to be able to hibernate. I have sleep apnea. So sleep is a problem. But humans don't hibernate. But there's a ton of other mammalian species that that do. And sometimes I do feel, though, that my teenager hibernates, but that's a different issue. So, but, what what is interesting to you about hibernation from a physiological point of view. What what goes on with metabolism or gene expression during hibernation, that's that's not found in humans, but that could be relevant to human health?Ashley Zehnder: Yeah, I think this is a great question, Harry, because I think both Linda and I came to fauna from different backgrounds. I came from veterinary science, Linda from comparative genomics. We can go into our details later, but neither of us really appreciated the amazing physiology of these species. There are some of the most extreme mammals on the planet, and there are hibernating bears and literally every group of mammals. Right. This is something Linda specializes in. But there are primates in Madagascar that hibernate very similar to the 39 ground squirrels that we tend to work with. So it's this really deeply conserved trait in mammals, including primates. And, you know, it kind of highlights for us what our genes can do when they're adapted for extreme environments. And so that's kind of the lens that we take when we look at hibernation. It's how do these species protect their own tissues from being nearly frozen for six, seven months out of the year, having to protect their brains, their hearts, all their vital organs? They're not eating, they're not drinking. They're not moving for these really deep bodied hibernaters. When you think of 100 kilogram animal that's not eating for seven months, how do they survive that? Right. And it has to do with metabolic rates that change 200- to 300-fold over the course of a couple of hours. It has to do with oxygenation changes and protection from oxidative stress and ischemia reperfusion. And so if you look at a tissue by tissue level, you can start to see how these animals are finally adapted to protecting themselves from from damage. And then we can start to say, well, this is similar damage to what we see in human diseases. And that's why this is such an interesting system, because it's so dynamic and because it happens across so many groups of mammals, it really lends itself to this comparative genomics approach that we take to drug discovery.Harry Glorikian: Yeah. Because I was wondering sort of like what ways of healing from different sort of traumas and conditions do hibernating animals have that that humans don't, that we sort of maybe wish we did? It's sort of like, you know, almost Marvel or one of those things where you like go to sleep, you wake up, you've totally healed again, which kind of be kind of be cool. Yeah. So, you know. But when did scientists first begin to think about whether having a better understanding of hibernation might help us solve? Some of these riddles that we have in human health. I mean, it surely it can't be like a new concept. It has to go further back. I mean, what has changed recently to make it more actionable? I mean, is it, you know, omics, costs coming down that are making it easier, computational capabilities that are, you know, making all these come together? I mean, those. What do you guys. What's. What's the answer? You guys know the answer better than I do.Ashley Zehnder: I'll comment on a little bit on the physiology, and I will let Linda talk about the data revolution, because that's that's really what she knows very intimately. So from a physiology standpoint, these are species and not just hibernaters, but a lot of other species that we've been studying since the early 1900s, 1950s. I mean, these are some of our earliest biological experiments and our earliest understandings of biology. We're not necessarily done by studying humans. A lot of that was done by studying natural disease models, right? How did we figure out that genes cause cancer? So it's a little bit of a tangent, but bear with me, it was not by studying human cancer, it was by studying Rous Sarcoma Virus and how that virus picked up bird genes and then turn them on. Right and other in other individuals. So but then kind of this almost the same year in 1976 that we figured out that genes cause cancer by studying chickens. 1974 we figured out how to genetically modified mice. And we sort of figured out that like, okay, maybe we don't need to study natural biology anymore. And so I feel like we sort of lost a lot of those skills and figured out we had humans and we had model organisms and we were done. And I think now we're kind of in this renaissance where people are realizing that actually there's still a lot of natural biology that we can learn from. But it's being powered now by this data revolution and the decrease in cost and sequencing and availability of omics data like RNA. Seq and then I will pitch that over to Linda because that's really what she knows best.Linda Goodman: Yeah, yes, absolutely. You know, Ashley's right. And I think just to add on to that, that there was this issue in which there were a lot of field biologists out there working with these really fascinating hibernating animals. They knew a lot about what these animals could do, the extreme environments they were exposed to, that they could overcome, they could protect all of their tissues. And there was so there was a group of field biologists who knew all that information. And then on the other side, you have all of these geneticists who are studying the genomes of probably humans and mouse and rat. And they weren't really talking to each other for a long time. And I've been in the genomics field for at least a decade, and not until very recently did I even hear about all these amazing adaptations that these hibernating mammals have. So I think some of it was just a big communication gap. And now that the genomics field is starting to become a little more aware that all these exciting adaptations are out there that we can learn from, I think that's going to be huge. And yes, of course, it certainly does not hurt that there's been a dramatic drop in sequencing costs. We can now sequence a reference genome for around $10,000. That was unheard of years ago. And so a lot of these species that people would previously consider untouchables because they were not model organisms with a pristine reference genome, we can now start to approach these and thoroughly study their biology and genomics in a way that was not possible several years ago.Harry Glorikian: Yeah. I was thinking I was, you know, I was laughing when you said $10,000, because I remember when we did the genome at Applied Biosystems and it was not $10,000.Ashley Zehnder: Yeah.Harry Glorikian: Yeah. And it took I remember Celera, we had an entire floor of sequencers working 24/7 I mean, it was an amazing sight. And now we can do all that, you know, on a.Ashley Zehnder: Benchtop. Benchtop. Exactly. On a benchtop.Harry Glorikian: So. But, you know, it's interesting, like in a way, studying animals to learn more about disease mechanisms seems like a no brainer. I mean, we share a, what, about 99% of our DNA with chimpanzees. And for those listening. Yes, we do. You know, I'm sure there's people out there that, like, bristle when I say that. But what is it, 97.5% of our DNA with rats and mice. That's why we use all these things for sort of safety and effectiveness of drugs meant for humans. But. Still, I'm not used to drug hunters starting out by looking at animals, you know? Why do you think it's taken the drug industry, although I'm I say that very loosely, [so long] to wake up to that idea?Ashley Zehnder: Yeah. I think it's I think it's again, this almost reversal of the paradigm that exists today, which is let's take a human disease that we want to make a new drug for. Let's take a mouse and let's try to genetically manipulate that mouse to mimic as closely as possible what we see in the human disease. And those are always imperfect. I mean, I did a cancer biology PhD at Stanford, and there's that trope of like, Oh, if I had a dollar for every time you occurred mouse in a human right, it would need to work anymore. That's replicated across many fields, right? They're not good models. And so we're saying like obviously that doesn't really work for discovery. It's fine for preclinical and safety and you have to use those models. But for pure discovery, that's not where you want to be, right? Instead, you want to take the approach of saying, where has nature created a path for you? Where is it already solved this problem? And I think there are companies like Varian Bio who are doing this in human populations. We're saying, let's look at humans that have unique physiologies and a unique disease adaptations. And of course then you have to find those niche pockets of human populations.Ashley Zehnder: So that's not a not a simple problem either. But the approach is very analogous. What we're saying is we can use that rare disease discovery approach and just expand that scope of discovery. Look at highly conserved genes, look at how other species are using them to reverse how phosphorylation in the brain to repair their hearts after damage, to reverse insulin dependence. To heal, we'll heal their tissues or regenerate stem cells. Let's just see how nature did it right and just mimic that instead of trying to fix something that we artificially created. So it's literally reversing that paradigm of how we think about animals and drug discovery. But you have to know how to do that. You have to know which models are correct. You have to know how to analyze 415 genomes together in an alignment which is really complicated. Linda knows how to do that, so you have to know how to do it correctly, although you could screw it up very badly. So there's a lot of expertise that goes into these analyses and also again, the data availability, which wasn't there nearly a decade ago. So.Harry Glorikian: So I asked this question out of pure naivete, because I'm not sure that I could sort of draw a straight line. But, you know, which drugs were have been discovered through research on genetic mechanisms of disease in animals. Is there, are there?Ashley Zehnder: You know, I think directly it's a new field. Right. So I think, Linda, you and I have looked at some examples of looking at drugs for narcolepsy, looking at dog genetics and studies, looking at muscle disorders in certain species of cattle that have naturally beefed up muscles and translating those into therapies. I mean, there are examples of looking at animals for things like genotype, right, came from Gila monster venom, although that's not strictly a genetic program. Right? So I think this idea of looking at natural animal models is a source of innovation. It's just that, again, the data wasn't really available until fairly recently, but we know the strategy works by what's been done on things like PCSK9 inhibitors in humans, right? It's a very similar approach to that. It's just expanding that scope of discovery.Harry Glorikian: So because you guys raised money and you guys are moving this forward, sort of and I don't want you to tell me anything that's confidential, but. So what was the pitch when you when you put that in front of everybody?Ashley Zehnder: It was really that, look, drug discovery right now is really been hampered by a lack of innovation. And we're really stuck in looking at these very kind of currently limited data sources, which is humans and again, these handful of really imperfect animal models. But we can take what we've learned from working with human genomics and really greatly expand the opportunities for a number of diseases that still don't have good therapies. Right. We've had the human genome for really close to 20 years now. We spent a lot of money sequencing it. And still, if you go back and look at the FDA approvals in the last two years, which I did by hand a while ago, or more than three quarters of those are not new targets. They're new drugs for a new indication or new drugs, same drugs before a new indication or they're kind of meta pathway drugs or they're drugs for which we still don't know the mechanism. It's some small molecule. It's been around since fifties. And so like where is the innovation in the top ten diseases of people still have it changed? So like where I pulled these two headlines right not too long ago, one from 2003, which is like the era of the genomics revolution. Right? And then one from 2019, which was the genomics revolution question mark. Right. Like we're still sort of waiting for it. And so what is that missing piece of data that's really going to allow us to really leverage the power that's in the human genome? And to do that, we have to put our own genes in an evolutionary context to understand what's important. That's been that third dimension of genomics that's been missing. So it's really not necessarily about any particular species that we work on, all of which are amazing. It's really about using that data to shine a better light on what's important in our own genome. And so that's a lot of the pitches, like how are we going to use our own genome better and find better treatments?Harry Glorikian: Yep. Understood. So. You have a third founder, Katie Grabek. Right. So. Tell me about yourselves. I mean, did the three of you get interested in comparative genomics and hibernation? How did you come together? How did you decide like, oh, hey, let's do a startup and get this thing going in this area? So tell tell me the origin story.Ashley Zehnder: Linda, do you want to kick off?Linda Goodman: Sure. I think it all really started, Ashley and I initially started batting a few ideas around. We both had this understanding that that drug discovery today did not look outside of human mouse rat very much. And we both understood there was this wealth of animal data that's just waiting to be used and no one was doing it and we couldn't really figure out why. And we were having trouble figuring out exactly which animal we wanted to study and which diseases we wanted to study. And it just so happened that we lucked out. There was another woman in our lab at Stanford, Grabek, who had the perfect study system for what we were thinking about. She had these amazing hibernates our animals that have exquisite abilities in terms of disease, resistance and repair. And once she started talking about all the amazing phenotypes these animals have, we thought, wow, that would make a great study system to make the next human therapeutic. Yeah. And I think it's interesting that both Katie and Linda have human genetics PhDs. Right. So I think both of them and Linda can expound on this. But from Katie perspective. Right, she she went in to do a human genetics Ph.D. trying to understand how genes can be used to improve human health and shouldn't be rotating the lab of somebody who studied the 39 ground squirrel and said this physiology is way more extreme than anything we see in humans, but they're doing it using the same genes.Linda Goodman: What are those genes doing in these animals that we can adapt for human therapeutics? And so she brought that work with her to Stanford and was really one of the preeminent researchers studying the genetics and genomics of these species. My background is I'm of Marion, so my clinical training is in exotic species. So as a clinician, I treated birds, mammals, reptiles and saw that they all presented with different kinds of diseases or in some cases didn't present with diseases like cancer that were super interesting. And then coming to a place like Stanford to do a PhD, it was working with a bunch of human researchers, human focused researchers. They're all generally human researchers, but you know what I mean? It's a little bit tricky with the nomenclature. Generally, I have my doubts about, you know, maybe there's some chimpanzees doing research somewhere, people studying human diseases, right from a human lens who are completely ignorant of the fact that animals often also had these disease traits or in some cases were resistant to them. So there was this huge disconnect there of of biologists and veterinarians and physiologists who understood all these traits across different species and the people who knew the molecular mechanisms, even though a lot of those are shared.Linda Goodman: And so one of the things that I found really interesting just from a cancer perspective was that a lot of our major oncogenes are highly conserved because these are core biological genes that if you screw them up, will give you cancer. But there's an evolutionary pressure to maintain these genes. And so there's a reason why they're conservative, because they're really important biologically, and that's true across many other diseases as well. So from that perspective, I was really interested in this intersection of human and animal health. I always wanted to do more genomics myself and just never had had the training. Linda had always been interested in veterinary science, and so we kind of immediately started collaborating and saying, Look, look, there's a huge opportunity in this, again, third space, third dimension of genomics that people are not looking at. What do we do trying to start a comparative genomics company? I'm using air quotes here for the podcast listeners is a little bit broad. Where do you start? And I think Katie really gave us that start in saying, here's a model. We have a biobank of samples that are proprietary to fauna. We have an expert in this field. We have a model that's good for so many different diseases. Let's prove that the process works here and then we can expand into multiple disease areas.Harry Glorikian: You know, you got to love, people I think, underestimate that magic that happens when the right people get together and the spark happens, right? I mean, I'll take that. Any day. I mean, I love coming up with a plan and then, you know, working to the plan. But when it happens, when the right people in the room and they're all get excited, those are those are the most incredible start ups, in my opinion. Yeah. So you're starting off with targets in heart disease, stroke, Alzheimer's, diabetes, very different areas, right? Cardiovascular, neurodegenerative and metabolic. So. Why start with those areas in particular?Linda Goodman: So I think for us it was really again showing showing what we can translate from this model. So some of the phenotypes that we see, the traits that we see in the ground squirrel, which is predominantly one of the species we use for our work, is that they're exquisitely resistant to ischemia, reperfusion injury. So the kind of injury that gets, if you have a heart attack and you go and get the heart attack on block, you get this rush of warm, oxygenated blood back into your heart that can actually be damaging. And that's a lot of what causes damage after a heart attack, what these animals happen, they do this 25 times over the course of a 6 to 7 month hibernation cycle. And if you look at their hearts in the peak of one of these periods, there is an upregulation of collagen, which is cause of fibrosis. There's an upregulation, there's histologically, there's a little bit of damage. It's less than you would I would have, but there's a little bit there. But if you get to the end of that whole cycle and look at their hearts, they look normal and they do it again next year. Right. So you and I could not survive 25 of these attacks over six or seven month period, right? Obviously not. So let's pick the strongest phenotypes we have in these animals and let's show that we can use information from that and come up with genes and compounds that are protective in our more standard models of these diseases.Linda Goodman: And that's what we did really with the first round of data that we had is we generated four genetic targets and two compounds that came out of the heart data that we had from hibernating and that we tested them in human cardiomyocytes in a dish and said if we take oxygen and glucose away from these cells, they get really unhappy and die and we could double survival of human heart cells in a dish. And then we said, okay, great, let's actually move this into animals. And so we used AAV or some of these viral vectors to then knock down genes in vivo in hearts of rats. So we literally tied off a coronary artery and then let the blood come back in and saw that we could almost fully protect these hearts from damage by knocking down genes that we found in the hibernating data. So it was really closing that loop and saying, where are the strongest traits? Can we show that this works? And then it was really figuring out where are the really large areas of unmet need. And so in terms of metabolism, we end up connecting with Novo Nordisk, which is a publicly disclosed partnership. They are very focused on obesity. We have a model that increases this metabolism, 235 fold over an hour. Name another model that can do that, right?Harry Glorikian: I need that. I need that. I need like, because...Ashley Zehnder: We all need that!Harry Glorikian: I could get rid of a few pounds right around here.Linda Goodman: Exactly. So then it's really just figuring out where are the unmet needs, who is really interested in these areas we're looking at and do we have unique data that speaks to those models? And that's really we just try to be guided by the biology and saying, where do we have unique data sets that can answer high unmet needs?Harry Glorikian: Okay. Well, all I mean, all sounds super exciting if we can make the translation, you know, in the right way and find those targets. But. You guys have built up a significant biobank, right? I understand you have a huge database of genomic readout from various hibernating animals. Can you tell us a little more about the extent of that biobank? How did you collect the data and how unique is that database in the industry?Ashley Zehnder: Yeah. Linda, do you want to talk a little bit about the data sources that we're currently using at Fauna?Linda Goodman: Yeah. So maybe, you might be the best person to talk about the Biobank and then I can talk about all the other data sources layering on top of that.Ashley Zehnder: Yeah, I'll talk a little about the BiobanK. So we have yeah, we have a number of different data sources. The Biobank is one of them and probably one of the main ones that we use. So Katie, during her PhD, built a really unique biobank of very precisely time tissue samples from 39 ground squirrels across the whole hibernation cycle. And the reason why that timing is so important is because the cycle is so dynamic. If you don't have really precise sample timing, you end up with a big kind of smush of data that you can't tease apart by having really precisely timed data points, you can separate these genes into clusters and know exactly kind of where you are in time. And that timing relates to the physiological injuries that we study. So we know what time points their hearts are protected because those physiological studies have been done. We've looked at those time points very specifically. So we have that biobank of samples that we in licensed as founding IP at Fauna CANI literally drove it across the country in a U-Haul because we didn't trust anybody to move it. So that's that's now in our freezers and Emeryville with a cadre of backup batteries to protect it.Ashley Zehnder: So that's the founding data that we have. And that's been really crucial because I look at other companies trying to use data for drug discovery, particularly in the early stage. A lot of it is kind of publicly available data or cell lines or kind of shared data sources. And part of what is unique about font, as we literally have truly novel data sources that we're starting with that are wholly owned that we control and we know the quality of those. So that's really the Biobank that we have is and it's 22 different tissues. I mean, it's brain, it's kidney, it's lung, it's hard. It's liver or skeletal muscle. Right? Pretty much every kind of tissue you would want in that founding biobank. But then on top of that, I think what we've done with the other data is super important. Yeah. And so we layer on top of that all sorts of publicly available data and also data we've been able to source, such as human data from the UK Biobank. But I really want to hit on the point of, of why the model species hibernate or data is so different. All of the other data that most people work with is trying to compare animals that are healthy to animals that are diseased, or people that are healthy to people who are have disease. What's really unique about the model species that we're working with is we're trying to figure out why they have these superpowers in terms of disease, resistance and repair.Ashley Zehnder: So it's kind of the other end of the spectrum that we're making this comparison between a normal, normal hibernate or during, say, the summer months and then a hibernate or that has gene expression patterns that mean that it's resistant to many diseases and it can repair tissues when it gets damaged. So it's actually quite different from the normal types of comparisons that others would make. But yes, and then we integrate publicly available data from sources like Open Targets Reactance. And one of the other data sets that we work with that's that's valuable is that we go back through literature that is relevant to the disease, indications that we're going after. And we have a team of curators that mines these papers that where the biology is relevant and we integrate those transcriptomic studies generally into our database. And that that really helps with our comparisons. And I can kind of give you an example of the way that we would do this type of cross-species analysis compared to what other what others in the industry might do if they were just looking at humans or say, just looking at mouse and rat is that, you know, if you're if you're just looking at at a human study and you're trying to say, look, for what genes do we think are involved in heart failure? You would look at, say, transcriptomic, differences between healthy human hearts and failing human hearts.Ashley Zehnder: And then you would have some type of gene list where you'd see the genes that have differential regulation between those two groups. And it fa not we we look at that type of data and then we also look at hibernate or data and then we can compare that. And that's really where the magic happens because we can look at hibernate hours when their hearts are protected during the winter months. So we have an example of these are genes that are involved in protection and then compare that to the summer months where they're not protected. And then we can integrate both of those to analyses so we can say what's really different about a human heart when it is failing to a hibernating heart when it is protected. And we do very fancy types of network analyses and then we layer on all of these data from external sources and the really exciting moments where we see these networks light up with the exact regulation patterns we are expecting that is relevant to our biology. Those are really fun. And I would say the other data source, Linda, that would be good to touch on is the genomic data, right? I think the comparative genomics data. So maybe give a little context on that. I think that really broadens the the views point of what we work with.Linda Goodman: Yeah, absolutely. So that's another data source that we work with. We have a collaboration with the Broad Institute that is one of the leaders of the Zoonomia Project that has in the neighborhood of 250 mammals in a in a big alignment. So we can do comparative genomics across all of these animals. And what we like to look for are comparing the genomes of animals that have a specific phenotype to others that don't. So for example, what is different in the genomes of hibernaters compared to the mammals that cannot hibernate? And we typically do this with how fast or slow evolving genes are, right? So if a gene doesn't accumulate very many mutations in hibernate hours, then it's probably pretty important for hibernation because there's a lot of purifying selection on that versus say, in other mammals that are not hibernaters, like like a human or a rat. It got a lot of mutations in it because it didn't matter as much for those animals. So that's another way of pinpointing the genes that are really important to hibernation. And we know, of course, that some of those might relate to the overall hibernation trait, but many of them are going to be disease relevant because they've had to evolve these genes in a way to protect their hearts and their other organs from these extreme environments they're in during hibernation.Harry Glorikian: So that, if I'm not mistaken, so did the Zoonomia Consortium, there was a big white paper about comparative genomics published in Nature.Ashley Zehnder: Nature last year? Yep. Two years ago. Yeah. A little bit.Harry Glorikian: Yes. Time seems to blur under COVID.Ashley Zehnder: Yeah.Harry Glorikian: How long have I been in this room? Wait. No.Harry Glorikian: But. Can you guys I mean, because doing comparative genomics is not, you know. It's not new necessarily, but can you guys summarize sort of the. Arguments or the principles of that paper, you know, quickly. And then, you know, my next question is going to be like, do you feel that Fauna Bio is part of a larger movement in science and drug discovery that sort of gaining momentum? So I'll, I'll I'll let you guys riff on that launch.Ashley Zehnder: Linda, you're you're the best one to do a perspective on that paper for sure.Linda Goodman: Sure. Yeah. You know, I think this is really born out of the concept that in order to identify the most important genes in the human genome, we need to be looking at other animals and more precisely, other mammals to see their pattern of evolution. Because if you see a gene that looks nearly identical across all other mammals, that means that it's really important. It means that it has been evolving for somewhere in the neighborhood of 100 million years, not accumulating mutations, which really translates to if you got damaging mutations in that gene, you were a dead mammal. Those have been selected out. And that's really how you can tell these are the key genes that are important to to your physiology, the difference between life and death. And you can't understand those things as well by just looking within humans and human populations. We're all too similar to each other. But it's really when you get to these long time scales that the statistics work out where you can see, okay, this has been this mutation has not happened in 100 million years. We don't see it in anybody's genome. So that is obviously very important. And that's just this other way of looking at our own human genome that helps highlight the genes that are going to be important to diseases. And I think, you know, another side to this paper related to conservation and the fact that a lot of these animals with really exciting genomes, the ones that are exciting to people like us, are those that have these really long branch lengths where they're they're kind of an ancient lineage. And that's really where the gold is, because that helps us even more understand how quickly or slowly some of these genes are evolving, and it related to trying to conserve some of these species as well.[musical interlude]Harry Glorikian: Let's pause the conversation for a minute to talk about one small but important thing you can do, to help keep the podcast going. And that's leave a rating and a review for the show on Apple Podcasts.All you have to do is open the Apple Podcasts app on your smartphone, search for The Harry Glorikian Show, and scroll down to the Ratings & Reviews section. Tap the stars to rate the show, and then tap the link that says Write a Review to leave your comments. It'll only take a minute, but you'll be doing a lot to help other listeners discover the show.And one more thing. If you like the interviews we do here on the show I know you'll like my new book, The Future You: How Artificial Intelligence Can Help You Get Healthier, Stress Less, and Live Longer.It's a friendly and accessible tour of all the ways today's information technologies are helping us diagnose diseases faster, treat them more precisely, and create personalized diet and exercise programs to prevent them in the first place.The book is now available in print and ebook formats. Just go to Amazon or Barnes & Noble and search for The Future You by Harry Glorikian.And now, back to the show.[musical interlude]Harry Glorikian: I should say congratulations because you guys did raise a $9 million seed round last fall from a group of venture funds, some in life sciences, some more general. Right. What does that funding do? What is it? What does that unlock next?Ashley Zehnder: You. I will answer that question. I do want to jump back to your other question that was kind of is this part of a larger movement and comparative genomics? Right. I think that's an important question. I think you sort of hit the nail on the head there. We were invited to a symposium in August of 2019 called Perspective and Comparative Genomics that was held at NHGRI in Bethesda. And I think there's a recognition and actually some of our grant funding is also through NHGRI. And I think there's a recognition from the folks who sequenced the human genome, that they don't have all those answers. And so it's an interesting time where we realize that there is this kind of other data out there that can help us really understand that better. And it does feel a little bit like a rising tide. And so that's that's something that I think is important to recognize. But in terms of the seed round, really, that was meant to expand the platform and the pipeline that we built with our initial funding back from Laura Deming and Age One and True Ventures, who led around for us in early 2019. It's really saying like that initial $3 million or so is really to say like, does this work or is this crazy, right? Can we it's just a crazy idea.Ashley Zehnder: And that's what we really started to generate those first few animal studies that said, yes, actually we can find genes and compounds from this data that meaningfully affect not only human cells, but animal models of human disease. And now we're really expanding into new disease areas. We're looking at areas like fibrosis. We're looking at areas like pulmonary disease. We've got some really interesting data coming out of animal models of pulmonary hypertension with a compound that we found on our platform. We've got the collaboration with Novo Nordisk, which of the five genes that they tested in animals? We have one that has a significant obesity phenotype. So I mean, 20% hit rate on a novel target discovery in vivo is not bad, right? So we've gotten to the point now where repeatedly over multiple disease areas, we've seen that between 20 and 30% of our either compounds or genes are hits, which shows us that this is not only kind of a we got lucky in cardiac disease, but actually this is a process for enriching for important drug targets. And now it's a matter of really expanding the pipeline. We brought on a really experienced head of Therapeutics Discovery, Brian Burke, who spent 20 years at NIBR running very early discovery programs and then seeing programs go into the clinic.Ashley Zehnder: He worked on drugs like Entresto and then worked on a couple of startups after that. So he's kind of gotten both big pharma and startup experience, and his job at Fauna is to really look at the menu of things that we're presenting him from an early research and discovery phase and picking the winners and really figuring out how to take them forward and also killing the programs that are less exciting to him for a number of technical or practical reasons. So that's been really, really helpful to have someone come in truly from the outside and take a look at the science at Fauna and say this is as good or better as anything that I've worked on before. I'm really excited to work on this, and that's been kind of a nice external perspective on on the science and the pipeline at Fauna. So that's really what the $9 million is for. It's really expanding a lot of the computational expertise and and progress and Linda can talk a little bit about that, but also just expanding into new disease areas as well.Harry Glorikian: Understood. So, you know, on this show, like, I talk a lot about, you know, technology, data, and how it's all affecting health care, which this all fits into. But one of the things we talk about a lot is how crappy, terrible, I should use, you know, terrible, right, electronic health records are in the lack of interoperability between them. And Ashley, you actually wrote a paper.Ashley Zehnder: I did, yeah, veterinary medical records are just as bad, actually, veterinary medical records are probably a little bit worse, if it's possible.Harry Glorikian: And to be quite honest, I'm sorry, I just hadn't thought about Fifi or Rover and their...Ashley Zehnder: Their medical records.Harry Glorikian: EHR. Is like is the problem bigger, even, when it comes to functional genomics? I'm trying to think of like obtaining and storing and analyzing 'omics of different species. I mean, who's working on this? Is that part of the Zoonomia consortium? Right. I'm just trying to think it through, like, how do you get all this information and then look at it across all these different species. And at some point, you know, look looking at it against humans also.Ashley Zehnder: Yeah. I'll let Linda talk about the genomics side. I'll comment on sort of some of the validation, some of the externally curated data that Linda talked about. I think this is actually becoming a really important data set. It was a little bit of a slow burn to figure out how to get it and to curate it. But there are a lot of studies now coming out and not just your traditional model organisms, but naked mole rats and long lived rock fishes and primate studies and bats and all kinds of people looking at genomics and RNA seek metabolomics and proteomics across these species that have interesting phenotypes. The problem is, every one of those researchers really heads down on their own species of interest, right? Nobody's saying, oh, well, actually, we're seeing the same genetic signature in these bats that we're seeing in the naked mole rats that we're seeing in some of these long lived fish. Right. But that data is not in a very friendly format. So we were like originally we were like, okay, we're going to write some scripts, we're going to try to pull some of the stuff out of supplemental tables. It's going to be awesome. No, no, no. We have very highly trained curators who work on this data and bring it in. And we have a very standard pipeline and a process and a way to normalize the data across different studies and standard ontologies and ways to clean up this data in a way that it can be integrated with the genomics coming out of the platform. And that is a tedious and painful and ongoing effort to bring in all this data.Ashley Zehnder: Now, we have data from well over 330 individual studies, over 30 species. I think Linda, you told me it was like more than 800,000 gene entries at this point that's curated and that's kind of growing month over month. So now that's becoming part of our defensible moat, is that we've taken the last two or three years, again, slow burn, pulling all this data together in a way that it can be reused. And now we can turn a paper around and put it on a platform in a week or two. So we're kind of always scanning for these studies. But yeah, it's, it's, it's out there, but it's not always in a usable format without a lot of pain and effort. And so we've kind of put that pain and effort into getting that data in a place that we can use it. And then, of course, the comparative genomics is like a whole 'nother level of complexity.Linda Goodman: Yeah, so I can talk a little bit about how we do that within the comparative genomics community and how we've done that for Zoonomia. Because I referenced before that we like to do these sorts of studies to examine the genomes of hibernate ers and non hibernate and figure out what's different. And you'd think it would be a trivial question who is a hybrid nature amongst mammals? But it's actually not. And so along with our collaborators Alison Hindle and Cornelia Santer, as part of the Genome Project, Fauna tried to go through and categorize every every genome that was in Zoonomia. So we're talking about around 250 mammals for is it a hibernater, or is it not? And you'd be surprised how often it was digging through literature from the 1970s and someone would say, this animal is not often seen during the winter. So we think it hibernates and it's not always the most satisfying. And so it is an extremely tedious effort, but well worthwhile to go through and say this animal, I'm very sure, hibernates. This one, I'm very sure does not. And then there's this third category of animals that were unsure about we're going to remove those. And it's tedious, but you have to do that part, right? Because if you do the analysis with bad data, you're never going to find the genes that you want. And Linda, I remember you telling me when you were going through this very painful process, I think your threshold for being a perpetrator, quote unquote, was that you could drop your metabolism like 50%. Correct me if I'm wrong, and humans could go down to like 40 like in certain instances, like humans are almost there. You know, it's it's hard to know when there is only one paper about it, but certainly there are some really deep meditative states and humans and low oxygen environments where, you know, we're getting kind of close to the area where we might say that that's a hibernated, but certainly not the duration that you get out of hibernation. But it's it's it surprised me to see how close how much how much metabolic flexibility there really is when you start to look at it. Yeah.Harry Glorikian: Yeah. We've got to go talk to the monks.Linda Goodman: Absolutely. Absolutely. You know, we have that in mind. It sounds like an interesting travel experience. Yeah.Harry Glorikian: So I want to jump back for a second because. You guys don't necessarily have from what I have pieced together, the normal sort of like startup story. Right. First of all, you're an all female founding team, right? Highly unusual, right? Not something I see every day. You guys started at an accelerator program in San Francisco called Age One.Ashley Zehnder: Age One.Harry Glorikian: And then you moved to QB3 and the East Bay Innovation Center.Ashley Zehnder: Yep.Harry Glorikian: And then I think they helped you with some paid interns.Ashley Zehnder: Well, we got some from Berkeley. Yep, we did.Harry Glorikian: Yeah. And then you went through a SBIR grant.Ashley Zehnder: A couple of them.Harry Glorikian: From the Small Business Administration. And then a small business technology transfer grant from the Human Genome Research Initiative at NIH. Right.Ashley Zehnder: Yep.Harry Glorikian: I'm hopeful, hopefully my notes are all correct. Talk a little bit about the on ramp or infrastructure today for sort of seed stage startups like you. I mean, what were the most important resources?Ashley Zehnder: This is such an important conversation. I'm really glad you're asking this question. We had a call with a reporter from Business Insider yesterday who was talking to all three of us about this early founder ecosystems in biotech and sort of East Coast versus West Coast ways of starting biotechnology companies. Right. And that is a whole do a whole podcast on that, let me tell you. But I will say that there are a lot of resources for, let's call them founder led bio. Right. In the West Coast, which is kind of the buzzword these days, but people really supporting the scientists who originate the concepts and training them to be founders as opposed to assuming that you need to bring in an experienced CEO to run a company at this stage. Right. So I think we were very fortunate to meet Laura Deming at Stanford, who is one of the founding VCs. And longevity before that was a buzz word, right? She was one of the first longevity funds, literally Longevity Fund, and is really been a champion of founders, starting companies and really training founders to start companies who are deep science founders. So we started in age one. It was the first batch of age one. We're still very close to that cohort of companies doing interesting things from machine learning and image analysis through pure therapeutics development. And then Laura really helped us, her, her. We asked her later, like, why did you end up investing in us? She said, Well, the science was amazing.Ashley Zehnder: This is totally a field with so much promise. I just needed to teach you guys how to pitch. The science was there, right? So she helped me just how to pitch and how to use less science words in our pitches, which we're still working on to some extent. But then it was this balanced approach of taking in some venture money to really support the growth of the company, but balance with some of this non-dilutive funding for specific projects where it made sense and some of that was some of that in the early stage is validation, right? Having having funding through groups like NHGRI, having an early partnership with a company like Novo Nordisk, which provided also some non-dilutive funding for the company, really validated all of the science that we were doing because we were first time founders, because we're a little bit outside of the normal profile. For me, I don't feel weird being a female founder only because 80% of veterinarians are female. Like, I'm used to being in a room with all women. You go to a bio conference, it's not the same thing, right? So for us, we're just we are who we are. Right. But it's helpful, I think, to get some of that external validation and then really be able to use that to to start to build on programs and show progress.Ashley Zehnder: And then it becomes more about the data and the progress and what you can do with it. So that's a lot of how we started the company. There's I said there's a lot of support in the West Coast for this kind of thing. There's great programs like Berkeley Foreman Fund Talks, which I worked, which I was in as well, just about logistics around starting companies. There's a lot of good startup accelerators. I've got a really amazing all of us, how amazing a network of founders who we can reach out to on different. I got four or five different Slack channels of founders that I could reach out to for all kinds of advice. And usually it's always good to have a company that's one or two stages ahead of you, like talking to folks who IPO'd or something last year is is not as helpful as folks who recently raised a series B, right. And figuring out what those milestones look like and then particularly those that have taken mostly money from tech investors like we have all the lifeforce capital who led our last round is also has funded some very good therapeutics companies, Sonoma Therapeutics and Second Genome and other therapeutics companies as well. So I think it's it's helpful to see how people balance the needs of the companies at different stages in what you need.Harry Glorikian: But so do you guys think that you could have started Fauna ten years ago? I mean, did the support systems exist for starting a company like this?Ashley Zehnder: Well, no, for two reasons. We couldn't have started Fauna ten years ago. One is the data just simply wasn't in a place that the company was a tractable strategy. Everything was still too expensive and we had really shitty genomes for a few species at that point. And B, I think there really wasn't the kind of groundswell of support for deeply scientific technical founders to start their own companies and train them to be the kind of leaders they need to be to run those companies for a longer term. So I think it's a confluence of those things and being in an environment like Stanford that really encourages people to to try startups, it's not a crazy idea. Like people don't look at you like you're your heads backwards. If you start to start a company at Stanford, it's like, okay, cool. Like, when are you launching? You know.Harry Glorikian: I think it's the opposite.Ashley Zehnder: Yeah, exactly. Exactly. Like, why aren't you have a company yet? Whereas you know, a lot, many, many, many, many other places like that is seen as a very strange thing to do. So I think the environment plays a huge role. Yeah, for sure.Harry Glorikian: Yeah. I think between East Coast and West Coast too, there's.Ashley Zehnder: That's a whole, we should have a whole 'nother podcast on that.Harry Glorikian: Yeah. Yeah, exactly. Well, I live here and I was I was born and raised on the West and I remember there and I came here and I was like, Oh, this is where you are not in Kansas anymore. Like, this place is different. So, I mean, I'm hoping that the East Coast is actually embracing risk a little bit more and sort of stepping out on the edge. But it's really slow. They don't call it New England for nothing. So. But, you know, it was great having you both on the show. I this was great. I we covered a lot of ground. I'm sure people's heads are spinning, thinking about, you know, you know, different animal species and how that's going to play into this. And I mean. It really does sound like I know we have to do the hard work, but there's a lot of computational effort that has to go on here to sort of. Make sense of this and bring it all together and align it so that you can be looking at it properly and make the right decisions going forward.Ashley Zehnder: Yep. Millions of data points coming together to find drug targets for sure.Harry Glorikian: So thanks for being on the show. And you know, I wish you guys incredible luck.Ashley Zehnder: Thanks, Harry, so much. This was fun.Linda Goodman: Thanks for having us.Harry Glorikian: Thanks.Harry Glorikian: That's it for this week's episode. You can find a full transcript of this episode as well as the full archive of episodes of The Harry Glorikian Show and MoneyBall Medicine at our website. Just go to glorikian.com and click on the tab Podcasts.I'd like to thank our listeners for boosting The Harry Glorikian Show into the top three percent of global podcasts.If you want to be sure to get every new episode of the show automatically, be sure to open Apple Podcasts or your favorite podcast player and hit follow or subscribe. Don't forget to leave us a rating and review on Apple Podcasts. And we always love to hear from listeners on Twitter, where you can find me at hglorikian.Thanks for listening, stay healthy, and be sure to tune in two weeks from now for our next interview.

The Otto Aviation Celera 500L made some big claims on fuel efficiency and laminar flow. After flight testing, how have those claims held up? We also discuss more Boeing 787 manufacturing defects, the GE9X sand ingestion tests, Joby news on certification and the CityHawk EVTOL. Learn more about Weather Guard StrikeTape segmented lightning diverters and aircraft lightning protection consulting services. Follow the show on YouTube, Twitter, Linkedin and visit us on the web. Have a question we can answer on the show? Email us!

Today's episode of Redefining Medicine features Robert Superko, MD. Dr. Superko’s research and clinical focus is on the metabolic and inherited aspects of coronary heart disease. He received his undergraduate degree from the University of California, San Diego, medical degree from the State University of New York-Stony Brook, and completed his internship, residency, and fellowship at the University of California, Davis. Over the past 35+ years he has completed multiple NIH trials including heart disease regression, coffee and lipoprotein metabolism, exercise and weight loss with a focus on lipoprotein subclass distribution, firefighter heart disease, and genetics. He served as Director of the Stanford University Lipid Research Clinic and Laboratory, the Director of the Cholesterol Research Center at the University of California-Berkeley, the Director of the American Heart Association Lipid Disorders Training Center, the Founder of Berkeley HeartLab, and Director of the Center for Human Genomics at the Saint Joseph’s Hospital/Mercer University in Atlanta, Georgia. His most recent investigation was the National Firefighter Heart Disease Prevention study which revealed metabolic and genetic contributors to the epidemic of coronary heart disease in firefighters. This work has now expanded to a National non-profit program that helps identify firefighters vulnerable to a sudden coronary event and works to prevent CHD events in this professional population that serves to protect the rest of us. Dr. Superko also served as the Chief Medical Officer of Celera corp. (human genome in 2001). He has published 166 manuscripts, authored 19 textbook chapters, and 130 invited presentations at National and International scientific meetings for a total of 320 publications. He is the recipient of many awards including the Larry King Physician Laurete award, the Montague Boyd Award for Best Research Article, and the Doc Hopkins award from the California American Heart Association for New Insights.

In this episode we discuss the folding wing tips of the Boeing 777x airplane, and what this engineering feat means for the plane's versatility. We revisit 737 Max troubles and discuss engineering testimony, plus dive back into the Otto Aviation Celera 500L and talk more about laminar flow and its claims of fuel efficiency. Lastly, we look at the AutoFlight V400 and talk through this EVTOL's possibilities in the market. Learn more about Weather Guard StrikeTape segmented lightning diverter strips. Follow the show on YouTube, Twitter, Linkedin and visit us on the web. Have a question we can answer on the show? Email us! Transcript: EP27 - Boeing 777x Wing Tips, 737 Max Troubles, More Otto Celera 500L and AutoFlight V400 News Dan: You're listening to the struck podcast. Dan: And here on struck, we talk about everything. Aviation, aerospace engineering, and lightning protection for aircraft radomes. All right. Welcome back to the struck podcast. In today's episode, we are going to cover a bunch of interesting topics. Number one. There was a recent, uh, engine fire causing a emergency landing with an . We're going to chat a little bit about that. Uh, and our engineering segment, the 777X. So obviously Boeing's had a lot of press recently, most of it bad, but we're going to talk a little bit about the engineering and the 777X and they're folding wind wingtips, which is pretty cool technology. Uh, we're going to chat more about the Boeing 737 max. Obviously the congressional report just came out today. We're not going to touch on that in this episode, but we are going to talk a little bit about some of the executives and the D the D design process and their defense of it. And then we're going to chat a little more about the Otto Celera. 500L - So the Otto aviation, they're one of their really unique jets, um, uh, planes. Uh, they have some crazy efficiency claims. We touched on it last time. We're going to chat a little bit more about it today. And then lastly, in our EVTOL segment, we're going to talk about the Autoflight V400. Uh, which is a unique cargo, um, you know, electric vehicle that's coming out of, and it looks like China and we will chat about it. And as well as maybe the, some of the bigger models that auto flight is going to be spring off of that one. So, Allen, how are you, sir? Let's jump right in the,  had an engine fire this weekend. Uh, I was at American airlines or this week and American airlines, Airbus, a three 20. They landed safely, but how common is this? How scary is this? I mean, what's your take here. Allen Hall: It's not common. And to have engine fires, obviously it usually raises some red flags with all the certification authorities when that happens and all the mechanics that are associated with it in the pilots too. So there'll be paperwork filed. Uh, it'll get reported, uh, and you, if you actually follow the aviation safety, Databases. You'll see those lists of incidences pop up. So you can actually scan, uh, how many times they've had brake problems, landing gear problems. Don't deploy flaps, don't work. It's actually pretty common. Now the engine fires a different level, right? Fire's bad on any airplane, but things that break are, are pretty common. So the driver here is that. Um, there's been a lot of, uh, engine related issues lately. Um, just because of the newer designs that are trying to drive efficiency way, way up. Uh, and when you do that, you can have some funky things happening. Remember all these engines today are all electrical, electronically controlled. There's a lot of hi Lee efficient, um, highly refined stuff going on inside that engine. So, and top of it, they're made not to catch fire. Right? So something has gone really wrong here and it'll the engine be pulled off, tore down, looked at right. And. Try to find a root cause to it and then alert everybody if it's related to some other issue that is going on it's, but it's a,

The Otto Aviation Celera 500L makes some big fuel-efficiency and operation cost claims. It can glide 125 miles from 30,000 feet, but can it deliver on these promises? We discuss a jetpack incident at LAX airport, the potential of a supersonic Air Force One, Hyundai's entrance into the EVTOL market, Gogo's sale to Intelsat, and Tesla battery technology that could change the aviation industry forever. Learn more about Weather Guard StrikeTape segmented lightning diverter strips. Follow the show on YouTube, Twitter, Linkedin and visit us on the web. Have a question we can answer on the show? Email us! EP25 Transcript - Can the Otto Aviation Celera 500L Deliver on Efficiency Promises? All right, welcome back. This is the struc podcast episode 25. I'm your cohost, Dan blewett and I'm here. Joined remotely by lightning protection expert. Allen hall, Allen, how are you? Great, Dan. Hey, uh, just reading the information about that auto, uh, aircraft design kinda looks like a fish with a propeller on the back. That's a pretty cool thing. New technology, sort of old technology combination between the two. Super dynamic. Yeah. We've got some interesting things to cover today. So with our, some of our news stuff, um, there was a man in a jet pack reportedly near LA lax airport. So that's terrifying. So we'll talk a little bit about that. Uh, Gogo has been sold to Intel set, so some movement in the radon because radon business, uh, we are going to talk about the auto aviation. Uh, they have a bullet shaped plane, which. That's some really interesting specs. I mean, it can glide up to 125 miles. They said. So the fuel efficiency is they're proposing is tremendous. Um, and lastly, we'll also chat a little bit about, uh, potential for a supersonic air force, one, a Hyundai entering the EBTL market. And some battery advances by Tesla that might make a real big difference also in the electric aviation. So first let's talk about this jet pack fellow. Uh, what is your take here? I, I saw this article. That they're investigating that there might've been a guy very close to the airport, which is obviously big cause for concern. Um, I mean, how do they regulate this stuff at the airport? Can't fly anything near an airport because an aircraft might run into it. So they're super cautious. Pilots are very aware of, of periphery peripheral things around the airport that could pose a safety risk to the aircraft. So, uh, seeing, uh, somebody in a jet pack suit or something of the sort, probably set off a lot of alarm bells in the cockpit and, uh, because. The sh he shouldn't be doing that, but I don't think they have found who, who, what, when, where this thing is like this, this is still sort of a mystery. As far as I can tell from the news sources, they haven't identified who was doing this. And is it, it wasn't a real person. Was it a dummy? Was it a drone of some sort who knows? Right. It could have been a high school kid with. So, you know, some sort of who, obviously they're not the kids aren't really at school right now looking to, you know, entertain themselves who knows. Uh, but it is a real safety risk. Holy moly. Well, just, I mean, we were talking about bird strikes last from last week. Yeah. We'll we'll we don't need to have his human strikes with people. Just stop there. And I mean, that's horrific, so yikes. Yeah. They got to stay, stay away from the airport, right? Yeah. And are the, you know, the iron man movies have. Uh, have a creative influence on a lot of, uh, people who are sort of quasi scientific and have the skill sets to, to make stuff. Right. So in today's world, it's not very hard to, to buy little jet engines that can propel you that have more thrust. Um, then your body weight and so they can lift you up. And, um, the guys off of, uh, MythBusters, do you ever see that episode or the one of the MythBusters guys built that iron man suit and was flying around in it?

¿Qué nuevas instituciones o movimientos sociales necesita España para consolidar la ciencia en España? ¿Qué debemos hacer como país para que la ciencia sea un pilar básica por y para el crecimiento económico, social y medioambiental de nuestro país y del planeta?. A todas estas cuestiones y muchas más, dan respuesta nuestros tertulianos de hoy, en la tertulia de la AEAC, en el marco de CIENCIANDO el espacio que pone la Asociación Española para el Avance de la Ciencia para que la sociedad conozca mejora a sus científicos e iniciativas sobre ciencia y sociedad. En la tertulia de hoy, intervienen: * Dr. Javier García Martínez. Presidente de la Academia Joven de España, Catedrático de la Universidad de Alicante y promotor de Celera. * Dr. Emilio Muñoz Ruíz. Ex -Presidente del CSIC, Profesor de Investigación emérito del CSIC y presidente del consejo científico y socio fundador de la AEAC. * Dr. Fidel Rodríguez Batalla. Secretario General de la AEAC y Director General de la Fundación de la Universidad Autónoma de Madrid.

José Antonio Álvarez López, CEO de Exes y profesor de economía en la URJC.Episodio número 58.En los tiempos en los que estamos los científicos y los investigadores tenemos una responsabilidad con la sociedad, es la transferencia de los resultados a la realidad, tenemos la obligación de aterrizar lo que investigamos para que sea útil.Eso es lo que estamos haciendo con la fabricación de materiales sanitarios con la impresión 3D. Mascarillas, protectores, máscaras, viseras, respiradores. Toda una comunidad de “Makers” que están haciendo el milagro. Nosotros usamos Gitlab.com, la URJC con Celera han construido ventiladores ya aprobados por Sanidad, en definitiva, todos sumando. Es el mundo solidario.Nosotros en cuanto a la tecnología utilizada con las impresoras, lo dividimos en tres partes:1-Diseño industrial, con SketchupMake que es muy fácil de utilizar, freecad, autocad, o el que cada uno domine. Blender para el renderizado, que es una parte esencial para dibujar las capas a fabricar.2-Calibración de la impresora, para que el estrusor y la cama estén a su temperatura correcta, para el que lo conozca, son los parámetros del Slic3r.3-Materiales, lo hacemos con plásticos, PLC y ABS, de distintos tipos, estamos utilizando todo el material que tenemos para las viseras, pero lo bueno es que no hay problemas de abastecimiento.En resumen, esto es cuestión de sumar todos.BeDigital es un espacio de divulgación de las nuevas tecnologías aplicadas a la transformación digital y la disrupción actuales conformado por varios espacios, BeDigital en Profundidad, BeDigital Conceptos y BeDigital en Femenino.SI ES TECNOLOGÍA, TIENES QUE CONTARLO.Ya sabéis que estos capítulos se presentan simultáneamente en Vídeo y PodcastSon CANALES ABIERTOS a todo el que quiera participar, queremos contar con todos vosotros. Si sois expertos en “lo digital” os queremos entrevistar, compartir lo que sabéis, ofrecer al mundo el conocimiento compartido, en abierto y gratuito. Nuestro PTM (Propósito Transformador Masivo): Mejorar significativamente el bienestar de las personas del planeta a través del conocimiento útil de “lo digital” y de sus aplicaciones.Suscríbete a nuestros canales: Youtube: https://bit.ly/2z6ekQ1Spreaker: https://www.spreaker.com/user/bedigitalTelegram: https://t.me/CanalBeDigitalIvoox: https://www.ivoox.com/bedigital_aj_15666377_1.htmliTunes: https://podcasts.apple.com/es/podcast/bedigital-conceptos/id1459368634https://podcasts.apple.com/es/podcast/bedigital-en-profundidad/id1459513186https://podcasts.apple.com/es/podcast/bedigital-en-femenino/id1470201033Spotify:https://open.spotify.com/show/5SK4Bi9ykCfOGJHbNgcdq0?si=lbKJsN_DTNazghqE8tEb7Ahttps://open.spotify.com/show/6Lraqe9D9y4Ef0B6YWQWQL?si=XB7_tKyxTUq73awlKgd8Twhttps://open.spotify.com/show/7rKcCPCStlMdlMJIQGD7xLEn nuestra web: https://www.be-digital.eso escríbenos a: info@be-digital.es

Deusto Business Alumni, en colaboración con la Fundación Banco Sabadell, presentó en Madrid el Programa Celera el lunes día 14 de octubre. Una oportunidad para nuestros/as antiguos/as alumnos/as, que deben aprovechar. Celera es un programa que identifica a jóvenes con talento excepcional en España para dotarles con las herramientas necesarias que les permitan potenciar todas sus capacidades personales y profesionales y que puedan así aprovechar al máximo todo su potencial. Cada año seleccionan a 10 jóvenes excepcionales para darles recursos, formación y oportunidades durante tres años. En el acto se contó con la presencia de dos Celeradas, jóvenes que participan actualmente en el programa, que explicarán la importancia y el impulso que representa el programa en su trayectoria: Rosa Narváez y Virginia Huidobro. En el acto se contará con la presencia de Rosa Narváez. G5, entró en 2019. Rosa es Senior Design Strategist y UX / Interaction Design Lead en Propelland desde 2017. En 2018 fue ganadora global del Hackathon de NASA Space Apps Challenge 2018 y en 2019 entró a formar parte de Celera. Sueña con inspirar a otras mujeres a adentrarse en el sector tecnológico y ofrecer soluciones a través de la innovación y el diseño para conseguir un mundo más accesible. Estudió Publicidad y RRPP por la UCM licenciándose con premio extraordinario y derecho en la U.N.E.D. Tras cursar un máster Dir. Arte y Creatividad en Madrid y Londres, comenzó su trayectoria profesional como creativa digital en Shackleton y Kitchen, ganando diversos premios en certámenes publicitarios. Además asistirán dos Celerados, jóvenes que participan actualmente en el programa, que explicarán la importancia y el impulso que representa el programa en su trayectoria. También estará en la presentación, Virginia Huidobro: G4, entró en 2018. Virginia es una todoterreno. Actualmente estudia Robotic Process Automation en EOI y está involucrada en diferentes proyectos como AI Saturdays, o Esto No Es Una Charla. Estudió Ciencias Ambientales en la URJC y lo compaginó con multitud de actividades transversales a sus estudios. Comenzó su vida proactiva co-fundando la asociación de UNION campus “Enciende tu Universidad”, donde buscan generar sinergias entre los estudiantes de diferentes ramas del conocimiento, una experiencia que le sirvió sin duda de lanzadera para lo que le deparaba su futuro. Fundadora y Team Leader del primer equipo Formula Student de su universidad “Fórmula URJC”, cuyo objetivo es diseñar y construir un monoplaza de competición junto con otros 40 estudiantes; participó y ganó el programa de “Mujeres para el Liderazgo empresarial”, una iniciativa de WomenCEO y todo ello compaginado con la representación estudiantil, donde ha llegado a ser miembro del Consejo de Gobierno y establecer el primer Consejo de Estudiantes de la URJC. ¿Qué es Celera? Celera es un programa que identifica a jóvenes con talento excepcional en España para dotarles con las herramientas necesarias que les permitan potenciar todas sus capacidades personales y profesionales y que puedan así aprovechar al máximo todo su potencial. Cada año seleccionan a 10 jóvenes excepcionales para darles recursos, formación y oportunidades durante tres años. Durante este tiempo, trabajan dos ejes principales: - Trabajar las competencias socioemocionales identificadas como las habilidades del futuro a través de una serie de sesiones grupales estructuradas en tres años. - Promocionar el capital relacional de los Celerados con su entorno de interés, personalidades internacionales y entidades de referencia, a través del desarrollo de los siguientes bloques: programa de mentoring, grandes oportunidades y talleres transversales. Ven el día 14, para conocer y resolver todas tus dudas de primera mano.

Meb Faber is co-founder and Chief Investment Officer of Cambria Investment Management and manages Cambria’s ETFs and separate accounts. He is the host of the Meb Faber Show and has authored numerous white papers and leather-bound books. He is a frequent speaker and writer on investment strategies and has been featured in Barron's, The New York Times, and The New Yorker. Meb graduated from the University of Virginia with a double major in engineering, science, and biology.   “The funny thing about investing in the computer age is we can now rely on an enormous library of investing ideas and concepts.” Meb Faber   Worst investment ever The young investor with a chip on his shoulder Like many young investors, when Meb got into investing as a young biotech engineering graduate in the 90s, he was full of vigor, overconfidence, and believed that he was the best investor on the planet. At the time, the US was hit by the Dotcom bubble and US stocks were the most expensive they've ever been. And so, it was a wild time that made crypto look basic. Wild times for investors It was a pretty wild time to be investing, but also, biotech was a big deal. The human genome was getting sequenced by the government as well as the company Celera, and so biotech stocks were also going crazy. Amid this madness, Meb identified a good stock to invest in, Biogen. This was in the early 2000s when biotech and pharma stocks were extremely volatile creating a lot of investment opportunities. The storm that is biotech stocks In most cases, biotech stocks, unless it's a monster like Pfizer, will have these binary events where they have a drug that's either going to get approved or not, in which case the shares will go 100% up or down. The whole company is leveraged to one outcome. And so that creates a lot of opportunity and volatility. So with Biogen, everyone knew there was a date in the future where the company would announce whether the drug was approved or not. Meb believed that the drug was not going to get approved. Choosing his best investment options Meb decided that he was going to balance his equity investment in Biogen and build a trade so that in the off chance it does get approved, he wouldn’t lose all his money. He bought both puts and calls with the understanding that there would be a very large market move. Now, if the drug did not get approved, he would make an enormous amount of money. If it did get approved, he would probably break even. By the time the day came to announce the decision, the options had doubled in value because the volatility had increased. Had he taken off a half or a quarter of his position at this point, as it was already making money, and sold it off he’d have doubled his money. He could even have sold his entire position and be done with it without having to wait for the event to happen. Too overconfident to think straight Meb was, however, overconfident and wanted to make tons of money. He waited for the results to be announced. The drug got approved. And as he had predicted, his position broke even, but he did not make a ton of money as he wanted. Now, if he had been thinking straight, he would have stuck with his original investment plan to exit the trade and move on. But his overconfidence led him to a decision that saw him make his worst investment. Meb decided to let the stock drift for a day or two and watch the market, hoping the stock would go up, and he’d squeeze out a little more profit. Well, what happened was the company decided for no known reason other than to themselves, that they should pre-announce earnings. This caused the stock to drop all the way right back down to where it was trading before the announcement. Suddenly, this made both sides of his positions completely worthless. So instead of making a fair amount of money before the announcement or making a little bit of money after the trade, he ended up not only not making money but losing all of his money. Lessons learned Consider the size of your position Do not put massive leverage on one position. You want to live to bet another day, and if your bankroll gets taken away, you can't bet, you're finished with the game. So position sizing is really important. Always have an investment plan If you're going to place a trade, come up with a plan and account for all the possible outcomes. Have a written portfolio policy. Your plan doesn't have to be complicated, make sure you have something written down so that when shit hits the fan in the future, you can refer to your plan and stick with it. Andrew’s takeaways Investing is like a contact sport Investing is just like a physical sport because every single thing that's happening in investing has an emotional and a neurological impact. This impact manifests itself in your body. As it is with any physical game, success lies in discipline and having a structured way of looking at things as well as having a plan. Have a plan and stick with it Having the best investment plan possible and sticking with it is a very hard thing to do but a necessary thing if you want to be a successful investor. Whenever you’re forced to sell,  remember that you don’t have to buy. When a trade comes to an end, you don’t have to execute another trade immediately. Stick with your investment plan. Don’t be sucked in by investment scams Often scams promise massive returns that aren't realistically attainable by using various derivatives or other exotic instruments. Options can be very complex, and can easily cause you to lose all your money. So be careful not to get sucked into some idea that you’re going to make a lot of money from some complex strategy. Actionable advice Have an investment plan, write it down, share it with someone, and make sure that you implement it. No. 1 goal for the next 12 months Meb is a skier and intends to try out a couple of skiing spots in the US in the next 12 months. As far as his work is concerned, his goal is to grow his business and enjoy doing it. Andrew’s books How to Start Building Your Wealth Investing in the Stock Market My Worst Investment Ever 9 Valuation Mistakes and How to Avoid Them Transform Your Business with Dr. Deming’s 14 Points Andrew’s online programs Valuation Master Class Women Building Wealth The Build Your Wealth Membership Group Become a Great Presenter and Increase Your Influence Transform Your Business with Dr. Deming’s 14 Points Connect with Meb Faber LinkedIn Twitter Website The Idea Farm Connect with Andrew Stotz astotz.com LinkedIn Facebook Instagram Twitter YouTube My Worst Investment Ever Podcast Further reading mentioned Jason Zweig (2007), Your Money and Your Brain: How the New Science of Neuroeconomics Can Help Make You Rich  

Richard provides the strategic and tactical framework to assist the Celera's financial team in reaching its goal of helping Celera's financial advisors with their advice‐centric growth and productivity objectives through the industry award‐winning Pentameter® process Visit themarkbishopshow.com for more interesting shows with Mark Bishop!

Invest Alongside Boston's Top Angels: Learn About Our Syndicates How his grandfather succeeded despite being blind inspired Shivang Dave, Ph.D. to change the world.  As an accomplished bioengineer and a founder, he aims to bring high-quality eye exams to the masses in India with a new device. The Madrid-MIT M+Visión Fellowship was crucial to building a capable and cohesive founding team for PlenOptika. Shivang was a cheery and inspiring guest; great interview! Some highlights: Shivang Dave, Ph.D. bio Shivang introduces his wonderfully multi-disciplinary co-founders: Eduardo Lage, Ph.D., Daryl Lim, Ph.D., and Nick Durr, Ph.D. Device looks like binoculars from Star Wars. Addresses a massive problem: 1.5 billion worldwide don’t have the eye glasses they need. The scarcity of trained vision professionals and the large size of optical equipment creates bottle necks outside rich countries. Market research with NGOs and other stakeholders pointed to the need for an accurate, portable and cheap autorefractor. As they spun out from MIT, they discovered that there was also a need for their device in high-resource setting such as the US. Founding story: Madrid-MIT M+Visión Fellowship, an MIT program set up with the government of Madrid to support 34 post-docs working together over 5years in identifying solutions for important problems. Daryl Lim, an optics-related Ph.D., discovered that poor vision was a major health problem. Nick Durr also had optics background. Shivang had worked on translating technology to address global health issues; Eduardo had built scanners used by GE. Plan was to create a work-saving device to multiply the capacity of trained professionals. Interplay between the perfect image and what your brain expects to see. PlenOptika and Zipline parallels. Shout-out to MIT Venture Mentoring Service (VMS). Leave a review on iTunes for Angel Invest Boston. Go to market strategy for PlenOptika. Business plan: sell the device. Massive market. Competition: disrupting desktop autorefractor. Other portable technologies; complementary? Slower to market but best-developed device. Fail fast not always applicable; particularly in medical devices. Backed up by independent studies. De-risks tech for users. Launched in India a year ago, launched in the US five months ago and both are going well. In 2020 expect to be expanding globally. Influenced by poverty in India and his grandfather’s blindness, Shivang felt compelled to do something to improve the world. First thought of being a doctor but realized that biotech could have impact on a much larger scale by creating medical tools. Publishing papers was not enough; wanted to take the technology out into the world. Worked at Celera Genomics; colleagues saw Shivang’s entrepreneurial spirit and urged him to pursue it. Grandfather was an entrepreneur despite blindness. Shivang’s fundraising advice for device companies; make sure to focus only on investors that invest in hardware. Chasing the wrong investors wastes a lot of time. Surround yourself with good advisors. Getting to no faster can actually save time. Sal say to angels, don’t BS founders; if you know you won’t invest, tell the founders right away. Shivang advises founders to steel themselves and their teams to the challenges of raising money and building the product. Don’t be surprised that it’s hard.

The roundtable is back at it again, but this time we are joined by David Jennings of RareBird101 and Wade Woodard of tater-talk to discuss some topics. Learn how you can be a part of Wild Turkey history by supporting RareBird101 on Kickstarter and if you agree or disagree with Wade on barrel finished bourbon classifications. We wrap up talking about limited editions and store picks because that's always a hot button for all. Show Partners: Barrell Craft Spirits is more than just bourbon, they blend rye, whiskey, rum and have a signature infinite barrel project. Find them at your local retailer. Receive $25 off your first order with code "Pursuit" at RackhouseWhiskeyClub.com. Show Notes: The week’s Above the Char with Fred Minnick talks about Joy Perrine, the first female bartender to be inducted into the Kentucky Bourbon Hall of Fame. Wild Turkey Kickstarter with David Jennings of RareBird101 - https://www.kickstarter.com/projects/rarebird101/wild-turkey-american-spirit News came out this week that the TTB is allowing "specialty whiskey" classifications to adorn the name bourbon on the label. Is this the demise of the bourbon law? Maker’s Mark released another limited edition. From a retail standpoint, isn’t this the easiest money that’s ever been made? When it comes to store picks should retailers care about what’s in the bottle? Taste vs Age, who wins? Will it sell no matter what? Thank you to Blake of bourbonr.com, Brian of sippncorn.com, and Jordan of breakingbourbon.com for joining as usual. Unknown 0:00 Everybody's a lot of chime in whenever they can. Jordan. Unknown 0:05 just lost anyone else. Did you know? All right, I mean, you know when your video wasn't breaking up, you might have saw. Unknown 0:27 Hey everybody, welcome back to Episode 196. of bourbon pursuit. I'm one of your hosts Kendrick Coleman. And this is the Community Roundtable. That means I don't have any news to talk about because all we talk about is the news. On the round table. We get some of the latest gossips and the fun cultural topics that we all love to hit on such as barrel selections, but a little bit news about us. We recorded a live podcast this week with Corky Taylor of peerless distilling company. Make sure that you don't miss out on our live streams and live recordings because we have Unknown 1:00 Another one coming up in May. Make sure you're following us on all our social media channels Facebook, Twitter, and Instagram. And you're going to be the first to know when we go live. Are you interested in partnering with bourbon pursuit? We're the most downloaded whiskey podcast across America. Check out how you can get your brand in front of a million bourbon drinkers per year at bourbon pursuit calm and hit the partnership button. Or you can send us an email team at bourbon pursuit calm. Now with that, let's hear a little message from Joe over a barrel bourbon. And then you've got Fred Minnick with the above the jar. Unknown 1:37 Joe from barrel craft spirits here. Barrell Craft Spirits is more than just bourbon, we blend rye, whiskey, rum and we have a signature infinite barrel project. Find us at your local retailer. Unknown 1:50 I'm Fred making this is above the char. If you walked into a low level bar in the 1980s you had a variable Unknown 2:00 little chance of getting a good Manhattan or old fashion or Mint Julep. Most of the bartenders were used to just slinging beer and porn, a little whiskey. Oh, nice or neat. And then came a young woman named joy Perrine. She came from the Caribbean islands where she served as a bartender at St. Croix and made all sorts of daiquiris and various types of from drinks and all kinds of banana frozen concoctions that made the island visitors quite happy. Local had never seen anybody like joy brainy. She stood behind the bar and slung mint juleps like nobody here before. She made Manhattan's and created special syrup that would complement Bourbons, unique to Kentucky. She was so amazing. That Esquire called her the bad girl of bourbon and the reason why she would tell you off if you Unknown 3:00 ordered a bourbon the wrong way in her opinion or if you boasted a little too much about what you thought you knew about purpose Unknown 3:08 because of her accomplishments in life, Joy preening was named in the bourbon Hall of Fame, the only female bartender to be inducted into the bourbon Hall of Fame. When she passed away two weeks ago, I thought about my relationship with a 73 year old. She was quick witted, would always tell you what she thought, but boy that she loved family. She loved her daughter, she loved my family. And I gotta tell you, if you were ever enjoy parade, nice presence and she made you a drink that taste that moment. It would last a lifetime. Unknown 3:47 her longtime employer, Dean corporate, died a few months ago as well. And I like to think that both of them are upstairs right now in the cloud somewhere, sipping on a bourbon Unknown 4:00 hope that I can only add to what Dean and joy did for the local community. And whatever you do in bourbon, whether it's consumer or promoted, I hope we can all live up to the standards that joy Perrine created. Unknown 4:18 And that's this week's above the char. Hey, did you know I got a new magazine out? Go check it out. It's on newsstands now look for bourbon plus and Whole Foods, Kroger, Barnes noble, and a lot of other places where magazines are sold. Hit me up on Twitter or Instagram at Fred Minnick. Until next week. Cheers. Unknown 4:40 Welcome. This is the 31st recording of the bourbon community around table is another favorite of bourbon pursuit because this is the opportunity that not only do we have a variable mix of some of the biggest bloggers and authors in the scene of bourbon here to join us, but we get to talk about Unknown 5:00 recent news and it's also the opportunity for fans for people that are in the bourbon community as well to join and watch this happen live and be a part of the live chat as it goes down so, Kenny Ryan and Fred here from bourbon pursuit team fellas, how you doing tonight? Unknown 5:18 Great. Unknown 5:21 3031 times down we had we had to mess up. Unknown 5:25 question Why do we do with the hardball? Unknown 5:29 Where's the bunnies? I'm trying to count all the towels on the bottom of the screen. I'm like how many people we got Unknown 5:37 is the round table as a bourbon family and I'm here at my cigar family and the lounge, smoking a stogie and just excited to get this going. I'm in my basement, looking at my kids two ways. Unknown 5:52 You know, let's do this pregame. know everybody's got a little bit better atmosphere but this is also the pre game that we're recording this about an hour before the Unknown 6:00 NCAA Men's National Basketball Championship kicks off. For me. I've got to still go with sec. So I'm pulling for Auburn tonight. Ryan, Fred, what about you all Auburn's not playing tonight? Really? Unknown 6:12 Where are you talking about 30 games? Getting? Oh, yeah, you're right. Sorry. Virginia. Virginia. Unknown 6:21 Tech. Yeah, I'm waiting for the one but they found you know, Unknown 6:27 start over from the topic. Unknown 6:31 I'm going I'm going to go actually have Virginia, Virginia. Virginia has had to crazy wins. So, like the probable odds of winning those games are like, not profitable. So probably they're going to win them. Go Texas Tech. Red Raiders. There we go. So we got our first three in. Let's go ahead and kick it off with our Cal Ripken of the Community Roundtable. Blake. Take it away. Yep. Just just continuing the streak all the way through undefeated Unknown 7:00 In the bourbon really count Unknown 7:04 I'm not sure Unknown 7:06 if you play if you throw a pitch and a game you counted as played but no so tonight well I'm Blake from burner burner calm and steel box calm so for tonight's game don't really have a dog in the fight Unknown 7:24 yeah birthday day of being a Florida fam. Ok now go back to back national championships a decade ago but Unknown 7:32 I think it'd be interesting to see Virginia when you know to go from the first number one seed to get knocked off by 16 seed and then go back and win the national championship the next year. That's pretty cool story. Unknown 7:44 Texas Tech and really I just have no connection to other than I'd like that bobby knight coach there for a few years but so my heart would say Virginia but I don't think they are they're going to win. I think Texas Tech actually wins. For going to do a spread. I'm going to say Texas Tech Unknown 8:00 by seven and Unknown 8:03 one up this Yeah. Unknown 8:07 bourbon or pick on that one if anybody wants to me. Oh, nothing's really Unknown 8:14 can I put my mortgage down on it? Unknown 8:17 That's a five star guaranteed. Unknown 8:20 Brian second quarter to go ahead and take it. All right, thanks. Yeah, this is Brian was sipping corn find me at bourbon justice calm or sipping corn calm Unknown 8:29 my team tonight I'm in protest so I'm still rooting for the cats somehow some way but since they can't win since it was robbed from us I'm going Texas Tech tonight the the probability that Ryan was talking about of some of those games that Virginia one and just not being able to put points on the board makes me think this is a Texas Tech kind of night. There we go. Thank you and an honor of one of our topics and one of our guests. I've got a wild turkey 1850 Unknown 9:00 Five the 1.8 proof nice and I've got a drink the rest of it because reminder to people quirks can still break after the initial opening so the rest of this is going down Unknown 9:13 somebody's gonna sleep really well tonight Cheers. Unknown 9:18 Jordan take it away. sure this is Jordan from breaking bourbon calm one of the three guys on the site visits for the Release Calendar. In Depth reviews can also find us on social app breaking bourbon, Instagram, Facebook, Twitter and Patreon. And for the championship game since Dukes been knocked out. I'm gonna stick with ACC and refer Virginia. Alright, and then we've got two other guests that are joining us tonight and they're always familiar faces to the podcast as well. First I'm going to go with Wade Woodard who is he's keeps the Tater library. He's got Tater talk calm. So welcome back to the show. Hi, good to be here. As you mentioned, I'm a whiskey geek. I have a blog side paid or hyphen talk. com Unknown 10:00 I am the compliance officer of the Texas whiskey Association. And we are within the next month launching a Texas whiskey trail with 14 distilleries on the Texas whiskey trail. Unknown 10:13 Let's see the game tonight. I one time was in Lubbock and I had an Aggie sticker on my car and I went into a restaurant and I came back outside and I had to slash tires Unknown 10:27 know I came here for other writers. I guess I had to go over with Virginia tonight and because it's working, you know, I brought out my Monday evening bottles here so I'm having a little while I'll turn feature of you might spark so here's just a poor Unknown 10:48 just happens to be above his computer as we're recording. Unknown 10:54 All right, and then David Jennings of Robert, welcome back to the show. Hey, glad you had me on. Unknown 11:00 Absolutely and you know, give a plug about you know what you do and that'll kind of lead us into our first topic tonight. Okay, well, I have a blog. It's rare bird one or one.com primarily reviews the wild turkey whiskies. I have some articles from time to time, there's resources there with the timeline and bottle codes and this kind of thing. And more recently, I just finished a first draft of wild turkey book, which I don't know if you want me getting into that or not right now. But anyway, I'm just glad to be on as far as a I'm just guys I'm just not into sports as much as you guys so in my house I'm rooting for wild turkey wins every night. Unknown 11:43 Also, the say is like is there something in your life that like doesn't revolve around wild turkey like at some point is your wife or your kids are just like God, we can just quit it just Unknown 11:54 a little bit, but I try to keep it you know, try to keep it in check. So anyway, it's all it's all fun. Unknown 12:00 And it's my passion. I mean, I really enjoy it. So, you know, it's, Unknown 12:04 it's hard. You know, if you're if you don't love something, you're not going to do it every day. But when you're really passionate about something, it just happens all the time. So that's that's my life on a weekly basis. And I David, I gotta tell you, when you when you reach out to me to read your manuscript, I was really honored and to see where you're going with it is fascinating and starting a Kickstarter campaign that is one of the it's one of the riskiest things you can do as an author to go out there and, and do that because you're putting yourself out there everyone's going to see what the donations are. So take us through that process. Why did you choose to go with the Kickstarter route? Okay, well, you know, Unknown 12:49 well, you know, how difficult it is probably back when you first started to get somebody to pay attention to you and and give you some type of publishing deal and or one that's even worth a flip and Unknown 13:00 I didn't really want to compromise. I was, Unknown 13:03 um, you know, willing to entertain, you know, publishing offers and that type of thing. But ultimately, you know, I, Unknown 13:10 I felt like no matter what I did, if I went that route, it was going to take a long time. And you told me, you know, we're looking at maybe February, the earliest, you know, something worked out, maybe later. And so, I felt like this was the year you know, I wanted to get something out there. This is Jimmy's 65th year coming up in September on September 10. And I would love to have a copy of this in his hands by that day. And I thought, well, I think I have a strong enough fan base to get just enough to make that happen, you know, hire a photographer and, and get some designed to have a nice looking book. You know, it's not going to be probably as nice as some of the other hardcover books out there. But it was enough. You know, I thought I could get enough together to make it something worth buying, you know, and I'll be honest with you, setting up Unknown 14:00 Kickstarter, it wasn't as easy as it was, when I set up my Patreon, there was a lot more verification to it, and you know, there was no guarantee that it would be approved. And so I put everything out there and tried to set it up as best I could and just kind of cross my fingers that they would sign off on it. I did. Unknown 14:18 And now and I did the math, and I'm like, okay, I just want to break even, you know, with this, you know, I don't want to, you know, you know, set myself upside down with rewards in this type of thing. So I sat down and did my math. I watched a lot of YouTube videos on how to run a successful campaign. Unknown 14:33 And so I did my research. And so I came up with 30 $500 Unknown 14:37 is probably enough to get the design photography, all this stuff together to get something out their own. We're a book can be purchased on the on demand basis, which I'm sure you're familiar with Fred, but like with Amazon, you can publish a book on demand. So you send them a PDF file, and they print the book as people buy it. And so I was just trying to cover the cost to get the book there. Okay. Unknown 15:00 And so Unknown 15:02 it alarmed me to find out, you know, within 24 hours. I mean, it was like I had like $1,000 already, you know, and then today I hit goal, like, you know, 10am or 11am or something. And I mean, and now I'm at like 40 $500 Unknown 15:21 or something you know, and the Bergen community. Unknown 15:27 Y'all are some good all of y'all. Well, David, I'll tell you, I'll tell you that Unknown 15:33 we will open up their wallets to turn, you know, like they're they do that to people that like, and you've always come off as a very genuine very fun person. And you get to know you and see if it's even more and then you got that South Carolina accent. You know, where's this all in? Bill Clinton Unknown 15:57 when I was sick Yeah. But yeah Unknown 16:00 Well, you know, guys, Unknown 16:03 it's, it's humbling it really is and I really appreciate it and appreciate you know y'all having me on. I'm going to continue with the Kickstarter is going on for another 5756 days or so. And everything you know, every penny I get above my goal is just going to go right back into the project whether I can make a classier book than I originally set out to. Or I can do some marketing. Like, you know, I've been thinking about some ads or this type of thing where I could at least try to, I'm not gonna be able to compete with the big publishers but I can I can maybe hit a target audience better than they can now. You can whip their ass Unknown 16:41 so let's let's kind of decent here today with 57 days left your auto pays to make $256,500 Unknown 16:53 Yeah. Unknown 16:56 Y'all keep talking like that. David, I will give you I'll give Unknown 17:00 Just some economics behind you know, books like I, you know, I've been writing books for more than 10 years now and my first my first my first whiskey book whiskey women, I had like 500 rejections and you know, if I had the access like Kickstarter or had the notion to do that I would have I probably would have done it but my advanced for that was $2,000 and so they don't like that typewriter manuscript Unknown 17:34 actually do Unknown 17:37 that. So you you actually stand you know for what how you're going about this. You probably actually stand to make you know, legitimate money off of it. You know, from from the book sales. If you're putting it all back and look like that's the goal was just to kind of see if I can, you know, upgrade the product because I would love to have something in my hands that is comparable to what you would find will book stand Unknown 18:00 I'm not cutting any corners with the Amazon print on demand. I mean, it's going to be a full color photo quality, highest grade paper that they have is going to be soft cover, unfortunately, because amazon kindle demand does not do hardcover. But if I continue to raise funds like this, I can have the Amazon Kindle demand for an option. And then I might be able to go to like book baby or Ingram spark or something, and print some hardcover additions. And those might have to be on a limited basis. It just depends, you know, but that's kind of where I would like to go with it. Unknown 18:31 The most important thing to me is that I won't something I want something in Jimmy's hands, that's what I want. If I can just tell his story, and of course, you know, there's a story in there and there's a lot about data in there. But if that is what I really won't, because Jimmy is such a legend, and I feel like it's it's his time to get even, I mean, he's had a lot of accolades. I'm not gonna lie, you know, he's had a lot of people Unknown 19:00 Give him various honors. But I think is there's a story there that a lot of people have not heard yet. And I think that this is the time this is the year his 65th anniversary at the distillery. And I really want to make that happen. And I want to make it happen this year. And it looks like it's going to happen now. Thanks to everybody. And I'm a Patreon supporters and, and everybody that's donated on Kickstarter, people that have tweeted, retweeted, done stories on Instagram, Facebook posts, emails, word of mouth, all this stuff really helps, and I really appreciate it. And I can't say thank you enough, I really can't. Unknown 19:34 Well, you've got more time to go here. You know, you, you hit a goal within three days, which is fantastic. You still got 5050 some odd more days to go here. So I kind of want to let you give, you know, sort of one last plug that are sort of on the edge or like maybe thinking oh, well, he's already got his funding, like why should I even bother to promoted or back is still but give some ideas of why people should still back it because of the stories and some of the content Unknown 20:00 You're going to be delivering inside of there as well. Okay, great. Well, again, I want to take any extra funds raised and increase the quality of the product and promote the product. And the purpose of promoting the product is to make sure that the story of the recipes and the Russell's and of wild turkey distillery in the Lawrenceburg area is put out there. And I think like said, it's a story that needs to be told. And it's the right time with Jimmy's anniversary. And then we had the one to one anniversary last year with Jimmy and Eddie's combined service. And so that is the most important thing to me. If it stays a self published thing where it's promoted on my blog, or my, you know, Twitter feed or my Instagram, it will reach people, it just won't reach as many people and so I need to make sure I can raise enough to get it to the right places, like bourbon plus, or something like an adverb plus would be a really cool thing. And so that is that's my goal. So I just have to raise enough money to do that. And I think the other Unknown 21:00 You know, there's content there that you will enjoy. And there's a whole appreciation section to it's not just history so if like history is not your thing if you're like I just don't really, there's there's gonna be a lot of reviews on there are tasting notes, my impression on different expressions, and I'm doing a lot of photography I'm paying for a lot of photography so the book is going to have a ton of bottle porn in it. It's going to have a lot of like cocktail porn. It's just yeah it's just going to be just loaded with excited just loaded with but just good porn at the end and I've got a good photographer so I it's I'm not it's not you know my stuff. Unknown 21:41 I you know, wait, I don't mind hitting up whiskey advocate either, but they're not on the show tonight. Unknown 21:49 I'm going to talk about bourbon. Unknown 21:51 Know your audience and you you talk porn. So Unknown 21:58 let's change the subject back to that. Unknown 22:00 You know, I'd like to get them in the bc i don't know if that's going to happen or not, I haven't really talked to compile it too much other than I did arrange some. Unknown 22:09 Well, at least I started the process of arranging to have the photographer come in and be able to take photographs, and make sure that there's no you know, questions there. Unknown 22:19 But, you know, it would be nice to get them in in the visitor center. I think it'll probably happen in time maybe after it's done and somebody has something to look at. I'm doing a very limited run this week, I sent a local printer Unknown 22:33 the book without pictures to have a just like a mock up late. So it'll be in the eight, you know, the five by 5.585 or whatever, you know, kind of book format digest format, and, Unknown 22:48 and I'm going to send those out to a few people to do some editing and some review. Might you might get your targeted at date for release. And how can how can your fellow panelists here help you okay. Unknown 23:00 I would like to have it completed in time to give it to Jimmy so that would be September 10. I'd have to have it in his hands so September to at least have a run of the book done by local printer so it would be exactly like what would be on Amazon but I can work with my local printer and have that rushed and done quick so I can do that habit FedEx. So you know I guess sep tember first at the absolute latest would be you know my deadline there but out to the world you know I'll put on their December because I didn't want to kind of overextend myself or make promises I couldn't keep because I don't know what the turnaround time is with Amazon and these things I haven't got into that. You know much research on that side because I'm more focused on just getting things done. But I put December but I'm guessing you know, it'd be more like october november sometime sometime like that were to get there before the holidays. That would probably be the best thing to do because it would make a nice Christmas present. I think you definitely want to time it with that. Unknown 23:57 The stocking stuffers they start emulating yeah Unknown 24:00 I'll request that is so that 50 bourbon stones I have. You know, Unknown 24:05 I just I never imagined how much I mean, you don't think about these things like indexing like, you know, like, Fred, someone does your index for you, you know? Yeah, I'm like, I'm gonna have to do that. And like, I started messing with Microsoft Word and I load Microsoft Word. I mean, it's got a lot of features, but it's just it sucks the creativity out of you do don't don't do indexing. I'll connect you with someone who will do it. He's got a great typewriter. Unknown 24:29 Exactly right. It doesn't say like we're getting out of the bounds of even when I even know. Well, thank you for it. I mean, seriously, because I played with it. And I'm like, Oh, my God, I'm gonna kill myself. Unknown 24:39 It was just not I want to create, you know, on the right. You know, I didn't do a review this week, because I was so focused on getting all this stuff together. And I love writing reviews. So it really hurt, you know, to have to take that hit this week. So if you've got someone that can do that, oh, that would be awesome for you to talk offline about the effect of Bernard stuff. I'm sorry. I'm on you guys. Unknown 25:00 Good, let's go on the rails here. So, Unknown 25:03 so I want to say, you know, David, thank you again for coming on and kind of give us an insight about your book for anybody that's wanting to help back as Kickstarter. And you know, with the Kickstarter, you get an actual copy of the book too. So you can get that link in the show notes for the podcast as well. But I kind of want to move it on to the next subject in this is where it kind of all happened in some sort of like Twitter spiral. Fred had tweeted about cast finished bourbon jumping the shark. Wade had a tweet about the TTP telling him that you could add flavor and color is so called a bourbon. And my head was about to explode and I said, You know what, let's just have both of these guys. Come on in and we'll just put it out there and kind of see who who's kind of feathers we can rafal if we're kind of tailing off the wild turkey thing there. So wait, I kind of want to toss it over to you to kind of talk about where where this conversation spiraled out of well, if you haven't bourbon, or a straight bourbon whiskey Unknown 26:00 You put it in a secondary task it becomes class type 641 whiskey specialties is no longer class type one on one or 141 which is bourbon or straight bourbon. And the team can you be has a chart that what products by class type can have flavorings added to them. And when you become a whiskey specialty, you're also allowed to add up to 2.5% harmless color flavoring event blending materials into a product. Unknown 26:33 So I think that's what Fred was talking about somewhat is that you can add these flavorings into secondary cast finished products and you don't have to disclose the fact and then we had a major producer just came out with a Unknown 26:48 bourbon that had been finished partially in wine cast partially and Sherry cask and they acted like they reinvented bourbon and they were calling the project directly on Unknown 27:00 The bottling they do have that you know what was done to it? bourbon finished and partially finished but we need people people like us because we're transparent talk about the product you're talking about. Unknown 27:11 Okay, Jim being legend. Unknown 27:15 So if you go on Twitter and type in legend, every single post, you'll see me posting the actual cola say no, it's not bourbon, whiskey specialties. Unknown 27:29 And this is something you've been on for a long time I've been I've been a lot more kind of just generally, I kinda I liked the category because I liked a lot of taste of them. But I've never really liked the fact that bourbon and straight bourbon are on these labels. And Unknown 27:49 this year at the San Francisco world spirits competition, I think a lot of people know I'm a judge there, and I had the special barrel finish category on my panel. Unknown 28:00 We're tasting these I mean it was like one was like over Sherry read one was over ported one had one was like three different wine cask finishes and that none of them had any notice what note whatsoever of a bourbon and and that was a moment for me that Unknown 28:22 you know where I realized that we're so far removed away from these things tasting like bourbon as a whole that bourbon should not even be on the labeled for the for a lot of these special barrel finishes. And when we create like a distilled spirits specialty or whiskey specialty that allows them to do a lot of the things that they want to manipulate it to remove it from the the actual flavor profile of the original spirit. I don't think bourbon should be on that label is you're starting to see a lot of these independent battlers. A lot of these craft Unknown 29:00 distillers try to separate themselves in the market. So instead of improving distillate or instead of having a good quality bourbon to begin with, they're trying to what they do and rum, which is add things to compensate for the lack of quality in the original spirit. And I gotta tell you, it, it has to have people like Booker know and Parker been rolling in their graves because this is the sort of thing that American distillers fought against in the late 1800s. Again in the mid 1900s. Every time there's ever been an effort to to mess with bourbon distillers have rose up and fought against it. And today, it's the exact opposite. You're seeing the larger distillers you know, push for more of these allowances within the within the federal government, and it bothers me, but I'm going to kind of take a different side of that. Unknown 30:00 You know, we talked to people all the time, every good every that does all the barrel shrink finishes, you're talking the angel's envy that Joseph Magnus is in the world, everything like that. And they look at it is, this is this is a new territory, this is a new angle, this is how bourbon is going to go to the next level because there's new new realms of experimentation. Whiskey is going to go to the next level in their opinion, but it's not bourbon. You know, we have the path back back 100 years ago in 1909, that basically said we couldn't had these adult all degraded spirits. And now we're getting back to, oh, well, let's add this stuff to bourbon again. So Unknown 30:40 I know what you're saying. I know what you guys are saying when when you support the category from a flavor perspective is very good. It's very exciting. But you know, at some point, we have to protect bourbon. And if we do not then so Unknown 31:00 Suddenly this has got there's going to be an allowance of coloring and flavoring to bourbon. And we have to protect that. And that's all this is about. That's always talking about that's all I'm talking about. I love I love the flavor of the angels a lot of the angel's envy products. I love the flavor of the Magnus products. I'm just coming to a point where you know there were there are people in that category who are taking advantage of it straight up taking advantage of it and adding flavor packets to it, you know, saying oh, well I got a little bit of a this is a pork barrel finish I just happen to have an extra bottle of Port there you know, so that is what people who are getting Unknown 31:41 getting flanked by those who trying to compensate for shitty quality distillate devil's advocate not disagreeing but just playing devil's advocate. So I guess more for waiting and Fred, so they come up with a new category called bourbon, whatever that defines the rules, regulations around how you Unknown 32:00 can finish a bourbon would that be something you're open to are now? Unknown 32:05 I would prefer not to use the word bourbon. Call it whiskey call it American last year called some new name. Well, I'm like read it should be protected bourbon. Yeah, you gotta like bourbon. I think I think what you have is them just not following the laws because I don't have a problem and it sounds like y'all do but personally I don't have a problem if they call it Kentucky bourbon finished in whatever barrels but I just pulled this bottle and it says a truly unique bourbon. That's not abiding by the TTP standards. And now on the bottom it says Kentucky straight bourbon whiskey and then a line below it partially finished in wine and share cast. So with that wording, I would have a problem with it. But I think it's you know, for me, I don't have an issue with it saying, you know, bourbon finished in whatever cast because that's what it is. You know, it's Unknown 32:58 pending that they always do that. Unknown 33:00 That those they start marketing efforts where they're just calling it bourbon and leaving off what was done to it confuses the lines and that's what Jim Beam is doing with this product. But interesting I contacted the TTP specifically about this Jim Beam legend product and as the compliance officer at Texas because I have 14 distillers that look to me the same what can we do own labels what's allowed? Wait, America, America looks to you know, Unknown 33:30 again, I want to make sure that the products they're putting out a fully compliant with all the laws and someone we're making some of these products. And so I sent the TT Did you know, direct question, you know, is this Jim Beam label fully compliant with the TTP laws and they basically came back and said, this label is compliant. So the TTP doesn't seem to have any problem with Jim been calling this product, a unique bourbon. Well, I don't know. I don't think I've never met. Unknown 33:57 Go ahead. Sorry. But no, I was just I was Unknown 34:00 I agree with Blake on the bourbon finished in but my devil's advocate question for Fred is Unknown 34:06 it's it's a subjective question to say when a bourbon finished in whatever kind of barrel no longer has the attributes of bourbon Unknown 34:16 so how do you how do you govern that Unknown 34:19 you know I just a bright line know finished it's finished it can't call a bourbon now again I'm not opposed to finishes and I'm not even really opposed to having you know bourbon necessarily on the label. But is it when is it the one is it the main one it's the main word on the label versus an amplified word. I think that it really where you know where we're getting here's here's the thing with with whiskey distillers really human nature's you give someone an inch, and they're going to take a mile Unknown 34:55 No, and that is where we are. I can't I can't remember who Unknown 35:00 What the brand was when I found out what it was, but it was finished in like three or four different tasks, and it was still in, you know, it's still on the shelf as a bourbon. You know, angel's envy is in one casks, whatever you think of them there in one cask makers 46. It's, it's one style, it's got French oak stays inserted, but we start getting past one barrel. I mean that that that's that is where people will start taking advantage of it. And then you're going to get into Celera. And you're going to get into all these other things that the Steelers are going to try to do to take advantage of it to stand out and to have used their marketing tools. You know, to get a very clickbait headline that will run rampant on something like men's health or gear patrol or Forbes or wherever. And that's that and I'm just telling you from a pure like readability standpoint, that Jim Beam story is all over the place. It is Unknown 36:00 All over the place and like what is what is drawing IR from Wade and a lot of other people is that fact that it continues to be called bourbon and, and being so different and it's getting put in that same kind of like innovation innovation bucket, as Unknown 36:19 you know, something like sweet mash, you know, and no one cares about sweet mashing. But to me that's innovation for bourbon. You know, to me that is real innovation. You know, the barrel finishes I again, I love the category. I love so much of the flavor of it. But we're getting out of hand and I just know in ROM, it's a shit show. You know, they say it's a hilarious system. They're not Celera. Well, I mean, the other thing is, is that when we're talking about these finish, Cass you all are no better than me. But I don't think there's a law or anything that states about how empty a certain cast must be, or how dry or how how age it has to be until days. I mean, Unknown 37:00 Could have six bottles of rum left in there or seller or Porter Sherry, it could have a few drops. There's there's nothing to say. Unknown 37:10 rebuild their barrels and then they refill them to write and that's how. Unknown 37:15 Yeah, exactly. Again, that's also what they doing wrong and and you know there's there's nothing wrong with that for for like creating a whiskey and another thing weight is something that is, is is of growth right now our blends we're seeing a lot of blends of various types of burdens. And you know, and this is this is another area where people can slip in a little bit. You don't see blend of straights, you know, what are you getting? So there's just there's just a lot of things where there's this incredible Unknown 37:51 I feel like taking advantage of an eager populace to drink bourbon. Unknown 38:00 Not to cut you off or but you know, it's funny the whole time we're having this conversation. So I think it's almost like the very front line has already been last a long time ago and where I think we'll take like wild turkey honey or Jam Jam stack or anything like that. So and I talked to a lot of people who don't normally drink whiskey or bourbon, right? Let's say, Oh, I had this really good bourbon was like cherry flavored, or I had this really good honey bourbon. I'm always like, oh, and I start to explain to them and they're like, Uh huh. So do you drink that bourbon? And it just goes right over their head, right. Like, the big distilleries. They won that battle A long time ago, because in their minds, people are reading the label. They're already especially with the brand. Yeah, right. And that's not even bourbon begin with. It's just a blend of the corn inverted right now. You know, they last a long time ago. Well, I think one thing we're seeing you ask how the how these products can be compliant with the TTP. If you exceed 2.5% and these flavorings, you would technically have to call it a flavored whiskey. We don't know how much product is in these cast when they add it in. So actually Unknown 39:00 Lot of these products get measured on time. Typically, they're probably exceeding that 2.5% level that's allowed by law to be added to it. So a lot of these products, especially when you start doing multiple casts, like Fred was talking about, they're probably exceed the 2.5% and probably legally should be called flavored whiskies. Wait, I have a question. Is there a definition for cask? I mean, what's the cask? Does it have to be a certain defined barrel? Or can it just be a wooden box mean? What's a cast? It may change soon. Unknown 39:34 I mean, what's a cask now? legally? There is no legal definition for you go. Matter of fact, in the TTP regulations, they call it an oak container. They never even say barrel or carrel cast, they call it containers, but they're changing that container finished whiskey. Unknown 39:55 Jefferson ocean So wait, wait. I'm curious what your Unknown 40:00 Think of this My belief is that if if, if the buck if it stopped with like something as simple as like angel's envy, I don't think we're having this conversation. And we were, I really respect what angel's envy has done, because they never they always are always very transparent that you know, there they are bourbon finished, bourbon finish rye finished and done but I mean, I don't know. I mean Bourbons bourbon by itself. That's the way and I think English stuff should be whiskey. That's just my opinion. Like, maybe I'm too old school because I grew up around it but why not in something man, just bourbon bourbon. You know, right. If you do that, we'd have to have like a whole spin off show of called like whiskey finished in podcast pursuit. You know? It works. Well. Unknown 40:55 Don't do it. Unknown 41:00 You know, but you know, as as we look at what the future is all right, so it things are taking off, and people are getting more influence, you know, throughout the, throughout the consumer base throughout the, the governance. And you know, what does that look like in 10 years, we've seen what this looks like now after really a 10 year explosion of barrel finishes. If in 10 years, this continues to escalate, Unknown 41:28 it is going to be a shit show and bourbon will be damaged. If we hold the line on what is bourbon. And if they would have stopped with angel's envy, we wouldn't have a problem. If they would have stopped at that style. We wouldn't have a problem but it didn't. Unknown 41:44 So I guess to kind of wrap this segment up if there's a call to action for bourbon consumers out there, Fred Wade, like what is what is that action that somebody should take? Unknown 41:56 Well, my saying is, if it's not straight, you must debate Unknown 42:04 He's been he's been teaching that one of Unknown 42:10 the next t shirts come Unknown 42:13 to bottled in bond because that's not getting messed with that's Unknown 42:18 that's even even more that's straight plus face well shit Brian then you're only going to have like 12 whiskies in your bar Unknown 42:26 you think bottled in bond is not getting mess with I my latest blog posts talks about a bottle and broad product really crossing the line and got over the world. Unknown 42:38 Damn cannot ride a way we reached out the way for pursuit spirits. Unknown 42:45 One more thing on this topic though, if people do like these finish whiskies, I did a little experiment recently of trying to make my own at home by just adding a little port or a little Sherry or a little grandma or gay directly to the bottom. Unknown 43:00 And let them married for 30 days and had a panel of 11 blind tasters taste my version versus the commercial versions and two out of the three my versions one easily hand down. So you can make these products at home by starting with a good straight bourbon base. I get a couple of things. One bottled in bond from a label labeling perspective is starting to be Unknown 43:25 you know, kind of mess with whistle pig has a bottled and barn. So you see, you see something like that that's out there. So we've seen flavored whiskies make it through the TTP as bottled in bond. So bottom the bond is absolutely You know, it can be Unknown 43:45 you know, penetrated and and i look at I always go back to ROM when we talk about this, take a look at the state of affairs ROM ROM is a there's not many really genuine pure producers left Unknown 44:00 So if you want if you want bourbon to turn into that, then let's just, you know, let let this continue to go buy more live legend. Unknown 44:11 Absolutely. Well, I mean, I think we, we definitely came away with some some learnings here. So anybody that's out there, make sure you are you're reading the labels, you know what you're buying, and you make sure you're looking at a lot of these guys blog posts because they go in depth and you'll be smarter because of the Unknown 44:30 bourbon pursuit wouldn't be possible without the support of our Patreon community, and with help of our following partners. Unknown 44:39 You listen to podcast, so you know that there's more craft distilleries popping up around the country now more than ever, but how do you find out the best stories and the best flavors? That's why we've partnered with rock house whiskey club. It's a whiskey of the Month Club who's on a mission to uncover not only just the best flavors, but those stories that you want to hear Unknown 45:00 From craft distilleries across the US, rack houses box ship out every two months to 40 states and rack houses April box there featuring a distillery that was located inside a former North Carolina prison. Whiskey prison, home to Southern grace distilleries. It's the prison you'd want to break into. Rock house whiskey club is shipping out two bottles from Southern grace distilleries including it's double gold award winning conviction small batch bourbon, which is the first bourbon ever to legally be age behind bars, go to rock house whiskey club. com to check it out and try bottle of conviction today. Use code pursuit for $25 off your first box. Unknown 45:43 But next I kind of want to talk about sort of the hype train that continues to build just around limited editions and everything like that. And that was because this past week in Kentucky there was the last edition of the Kentucky Wildcats Maker's Mark limited edition a release and makers Unknown 46:00 Mark does one of these every single year it's it's usually in the Kentucky, Southern Indiana surrounding areas, they'll make somewhere between 12,000 to 20,000 of these bottles. And of course, there's just people lined up around the liquor barns and total wines and other stores and the cost goes, and I look at this and I try to view it from a retail standpoint. And I'm kind of curious and kind of look at you all. Is this thing, the greatest scam that's ever been invented? Because it seems like retailers just make so much money over doing nothing like they can just sell a bottle like that in an instant. Kentucky fans will buy anything Unknown 46:39 goes more than just that. I think makers has this down to a science mean they've been not just Kentucky but they do. They've been doing this for years. It's like all right, what sports in one let's roll out the red white or red wax. Let's roll out the different colored wax. Let's slap it on there and people go gaga for it. Right I mean, including Unknown 46:57 the RNC and the DNC convention. Unknown 47:00 Two years ago Unknown 47:03 I've been doing that for a long time to rock the boat bottles for sure. Unknown 47:07 Yeah, Jordan, art. Yeah, there's a long tradition of that. Right. You know, with all the decanters and everything from years past that the distilleries would put out. Maker's Mark seems to be the only one who continues to keep it a long living tradition and yeah, I mean you know, I guess if you see it on the shelf in your dad kind of like bourbon and there's my sports team on there Okay, I'll buy it you know, it's well but I thought you bring up a good point blank, but those decanters were when bourbon really wasn't selling so people are going more from the higher they are in the bourbon right makers money and people are buying bourbon left and right now but they're still rocking it out but people people love it. I mean, you know and and so like about like to justify bottles, those things just sell out automatically, where now they just they have the market cornered because if Buffalo Trace comes out with a Kentucky Wildcats bottle, everyone's like, hold on a second. Somebody else Unknown 48:00 But you know but it just expects that maker so Unknown 48:05 it would be question that I see is that this these newbies out there thank you these are special edition that there's some kind of special bourbon in the in the glass Unknown 48:17 is Unknown 48:19 it's all 12 year old Maker's Mark everybody Unknown 48:23 know that the over over Maker's Mark Unknown 48:27 This is what overload tastes like it's pretty good Unknown 48:32 10 years could you release this Unknown 48:35 suckers and kept buying them for a while and then I realized that that's the same juices I just started using them as mixers like Unknown 48:44 bars like here you go but i think i mean i think certain brands right so you got makers but Woodford doesn't work there during bottle right? Yeah, we'll go guy off for that. I think each brand has their niche and they Unknown 48:55 who was it Secretary that for? Oh yeah, that was Unknown 49:01 That was that was good Unknown 49:04 that Secretary one Penny Chenery the owner secretary, it out that was that was one of the coolest experiences of my career was pick a whooping with her when she picked up on but these things are you know we can bitch about a lot of different things but this is a little bit to me of the spirit of just having some fun. You know it is what it is they've been doing it for a long time. It brings in outside outsiders interested into to the category. It gets new, you know new fan bases excited. I like it. Most people don't open the bottles you know. Unknown 49:45 You get Unknown 49:47 the last one I tried open was the Astros World Series bottle I had to take a blowtorch to. Unknown 49:56 Pretty sure somebody out here wanted a beam Unknown 50:00 Comes bottle and it came out just to the right Unknown 50:05 there you go. I've worked hard to get Unknown 50:08 I mean they could put just colored water in there and No One Unknown 50:13 No One No one else is saying it's kind of like you know we talked about it on community around table in the past of having a sign bottle. You're like well do I really want to open a book open up a bottle it's been signed it's like now you know I'll just open up something else so all those things just gonna sit on the shelf it's gonna be a cool decoration. I opened my son bottles so do i do yeah, you really are rare bird Unknown 50:43 just said he just sent me up so well. Unknown 50:46 Funny pitch right there. Unknown 50:48 Really is a night which bottle will they be making? Unknown 50:54 UVA Yeah, Texas Tech battle. Who knows? marketing. It's just marketing though. I mean it Unknown 51:00 It's not I mean it none of the juiciest are really being like you know enticed by these it's it's more for the you know the mass public that enjoys makers and beam and it's just I don't see anything wrong with it personally I think it's a smart move on their part makers has always had great marketing as kind of their thing you know cheers with him for doing it you know Unknown 51:23 maker says a really big collector seen as well right i mean there's there's guys who just have you know Brian Brian and Unknown 51:32 there's another guy but they you know they have hundreds of these bottles they buy every single one so you know get feed the audience as well which is pretty cool. Almost spent $200 on the Jaguars Makers Mark bottle one time from the AFC know what they did it for wasn't AFC Championship but but you did that because you were a sports fan? Yeah, no. Unknown 51:53 He did that background. He was playing Unknown 52:00 For now through me a touchdown the light was on the bottle my really about to pay $200 for Makers Mark Unknown 52:08 Alright, so I want to kind of just dovetail this into the the last topic tonight and this is again going to be more across on the retail side because I kind of pitch that one is kind of a build up because I look at it in a way that oh it's going to sell no matter what you know, it's it's limited blah blah blah even if it's not limited with 20,000 bottles in one state and you're only targeting us a sports team. It's still going to sell out no matter what. But then we start looking at some things when it comes to something we all love and talk about which is barrel pics and barrel selections. And there's some some retailers out there that they don't care about what's inside the bottle. They will get a barrel sample or they'll get a phone call and they say hey, we've got three barrels. We've got a nine, nine year nine and a half year and a 10 years ago. I just will take the 10 year old doesn't matter like littles will take it because it's age and that's what sells Unknown 53:00 So when so what do you all kind of think of this? Like, do you think that in this sort of this today's market that Yeah, age is going to sell a product? It doesn't matter what it tastes like or anything like that. You got a four roses. That's 10 years 10 and a half years old, it's going to sell no problem. Unknown 53:20 Yeah. Unknown 53:22 I mean, it just does or sorry, go ahead, Ryan. Oh, no. Well, Unknown 53:26 I won't say where we were and who this was for. But when Kenny and our two barrel cake recently, the master distiller we went through 10 barrels, and he picked why they go, Well, Unknown 53:36 this has gone to such and such store and we're like, that one sucks or something. He was like, well, they won't care. Unknown 53:43 Like along those lines, and so it's like, just always make sure where you're buying stuff. You know, who's taking the barrels, because a lot of times they're out there and they're just like, what's going to who they're not here I send them this one, you know, so that's my just take on it. Well, I think I forget who it Unknown 54:00 Was but they're talking about you know the difference between group pics and store pics is a pretty big thing or just trusting the store that's picking it you know we we had that experience that when we did our VCR Buffalo Trace pick there were a couple barrels and there were like this just isn't very good. And we're like you know how what happens these barrels It was like well somebody is going to eventually get these and you know it's just a store who says yeah, give me whatever it's going to sell out no matter what so it's another one of those things where it gets like hyped up hyped up all you got to get store pics you got to get store pics, and then all of a sudden just garbage starts flowing into store pics as well. Now it's like okay, you gotta trust who's actually picking these because otherwise you're going to end up with something that's worse than just what you would find on the shelf. Unknown 54:48 people our age trap, you know, Unknown 54:52 for for something with a big age on it up. I'll be honest with you like with knob Creek pics. The 1314 year pics are just not my Unknown 55:00 thing. Um, I mean, I like a more around the nine year mark from the ones I've tasted. Maybe that's just a personal preference. Unknown 55:07 But like with Russell's reserve, I recently had a pic from Justin's House of bourbon. And I was like, Unknown 55:13 This is amazing. I mean, the finish was a little short, but the nose and the palette was amazing. And I found that it was just barely cracking eight years and I was like, really, and it was from Camp Nelson F, which it from my experience has been very spicy. A lot of draw spice and heat. And this one was real fruity. It was very kind of almost like four roses, like like OBS or something. And I was like, this is just incredible. And he was like, Yeah, man, it was just it was barely eight years. I was worried you wouldn't like it. I'm like, I love this thing. And so you can't really go I didn't know what the age was going into it. And you can't just assume that because it's got double digits that it's going to be good on that is not true. Um, there are plenty of eight nine year picks out there have a various you know, four roses, Jim Beam, whatever that Unknown 56:00 Excellent so don't go by age but a lot of people fall for the trap 14 year knob Creek, you know gotta get it now you know, it's like I don't know you might want to taste it first you know? Yeah, totally agree. Yes Do they trust you they trust who's doing the pics you fall for the age age and they also fall for the proof a lot to right so you'll see the same thing it's like oh, it's high proof that's just as I'll get the highest proof or short barrel Oh, short barrel God. Exactly. Right. So you know, Unknown 56:24 it goes right back to what Brandi said. We got to know the people picking it. Right and just find a flavor profile of somebody else that has a similar you know, tastes as you do and just trust them. Yeah, so elixir spirits here commented in the chat and said it happens quite often. He had an eight year 11 month old SK he took delivery on over a 12 year OBS f however, the SK took one and a half years to sell versus the 12 year which only took six months. So yeah, I think it really boils down to people have this idea of of age statements when they go in and they don't really care. Unknown 57:00 Even said He even told customers that the sky tasted better too. So that just goes, Yeah, and people still buy it. And I think I think this is sort of the thing that we're starting to see. And and what I'm starting to see with some of the the retailers is that they don't they don't care about going and tasting it. They're just like, sure, just get the highest age put in a bottle, it's going to sell no matter what. Unknown 57:25 You don't see age statements on every other thing. So you're like, I think people get excited when they see like a higher age on something. Because your age statements are gone now. So that might be why Well, I think a little bit of this to you know, you're starting to see this is you know, we're talking about this but there's another coin to this is that the distillers are going to the distributors and saying, if you guys don't take this barrel, you're sending us a clear message. These rate retailers are not necessarily doing this by choice mean Yes, they are. Unknown 58:00 selling it but a lot of the bigger ones, you know, they're trying to keep that they're trying to keep their applications and their guys still go in there and get the sweet honey barrels. But they do take on a load that you know that maybe old forester doesn't want a knob Creek doesn't want, you know, doesn't have like a group coming in and selecting them. So it's not necessarily always the retailer's best interest to say no to these larger distillers who are dictating who is getting barrels right now, right? Yep, everybody's on the chopping block. So you got to just take it take what you can get Unknown 58:36 retailer here in Houston that they liked to have store pics, but not with their particular name on it. So they want some kind of designations. I'm going to stick around the bottle and it was a private barrel pick. But in case it's bad, they don't really want to have their name on the bottom. Unknown 58:55 I guess you aged storks sword because you know then people love it. You don't even get to play Unknown 59:00 It is the greatest thing ever. Yeah, it's when you have some side stickers. Unknown 59:07 Of course I go around that stores and randomly throw a little stickers out on that looks like a private barrel. Unknown 59:15 Just just help them run through Unknown 59:18 a bunch of unicorn stickers you know just Unknown 59:22 a unicorn that's that's probably the next good prank that you could probably pull next year April Fools just go to total wine and just start putting stickers on everything and just see what a few pictures out there and just watch people start running. Unknown 59:39 I bet the retailers would actually like that because like social media traction for them. Unknown 59:45 Absolutely. Yeah, press is good press. Good deal. So that's gonna that's gonna wrap it up for tonight's episode. I want to say thank you everybody for joining us whether you're live watching us through the chat and then also Unknown 1:00:00 Thank you to everybody here on the panel that joined us. So Ryan Fred thank you again I'm kind of want to go around the around the horn one more time to let people give an opportunity to do say where you blog and Yeah, kind of start closing it out. So Blake, we'll start with you, buddy. Yeah, Unknown 1:00:16 I'm Blake from bourbon or calm always great to be on here. Good to be back in the full aspect and not just a quick drop in so you can find me on Instagram Twitter, Facebook, do you are Bo and are also check out? seal box calm. That's s e ll be a CH s. We specialize in craft spirits. So check it out. Yeah, thanks for having me guys. Get all your bourbon delivered right to your door. Whether it's finishing a cask or not, it's still good. Unknown 1:00:46 All kinds of all kinds. Unknown 1:00:49 We can Yeah, whatever you want, you know, a lot of Unknown 1:00:54 new roof. Just a barrel landed last week. So that was that was a big one. It's already gone. So your YouTube like Unknown 1:01:00 You can get some of the other numerous stuff if you'd like. Unknown 1:01:03 Good deal Brian. Go ahead, go next. Alright, thanks. Thanks for having me on again, Brian with sipping corn and you can find the sipping corn calm and bourbon justice comm check it out on Amazon and through the comics website. Unknown 1:01:19 Good deal Jordan. You're up next buddy. This is Jordan one of the three guys from breaking bourbon. You can find us on social media at breaking bourbon along with Patreon. This is the site for our daily updates or at least calor along with our in depth reviews. Unknown 1:01:35 Good deal, and we'll just keep going in order we had before. So Wade, you're up next. Yes. My blog is Tater. hyphen, talk calm. Or for the folks that are listening in Texas. They might want to check out Texas with e.org Unknown 1:01:52 There we go. Big things happening in Texas. All right. Always, always, always big things. Unknown 1:01:58 And David, go ahead. Unknown 1:02:00 All right, well, if you want to read some wild turkey reviews, get a rare bird one or one.com. You can find me on Instagram at rare bird one to one, you can find me on Twitter at our bird, one to one. Unknown 1:02:11 And of course I'm on Patreon patreon.com slash we're bird one on one. And I have a Kickstarter as you probably heard about a book I've written about wild turkey. And I want to thank all my Patreon supporters, and the people that have pledged on Kickstarter and all my followers and readers and last but certainly certainly not least, thank you, Fred. Thank you for talking with me and guide me through this process and being so supportive. Appreciate it and I hope that everyone recognizes that you know, as passionate as I as I am about Wild Turkey, bread is passionate about bourbon, so thank you. Unknown 1:02:45 Good thing you're talking about Fred there because I was about to pull like a Bob Barker like the wheels, the wheels. Unknown 1:02:52 You're Unknown 1:02:54 trying hard for that bourbon plus, Unknown 1:02:57 discount. I gotta get that discount now. Unknown 1:03:00 You have private jet ads in there? Unknown 1:03:04 Absolutely. And so make sure you're following course bourbon pursuit on Twitter, Facebook and Instagram. You're also following Fred Minnick at all those different channels and supporting Of course, bourbon plus there as well. Right? Go ahead and close it out for us, buddy. Uber bus now. Thanks, guys for joining us as always, this is the shortest whenever I guess there's something going on tonight or something. Unknown 1:03:28 But no. Unknown 1:03:30 appreciate everyone. I'm a super excited for the rare bird Dave Jennings book. I'm super pumped. So please support that because I think it's going to be a great addition to anyone's bourbon library. But uh, Anyways, thanks, everyone, I guess go Cavs? I don't know. I mean, Unknown 1:03:48 so. I don't know. Yeah. We'll see what happens. Yep. Unknown 1:03:54 Well, with that, thank you, everybody, and we see you all next week. Cheers, bears. Unknown 1:04:00 Good Transcribed by https://otter.ai

ב-1998 היה פרויקט הגנום האנושי רחוק עוד שבע שנים לפחות ממטרתו השאפתנית: ריצוף מלא, בפעם הראשונה בהיסטוריה, של גנום אנושי. אך במסיבת עיתונאים הטיל חוקר שאפתן בשם קרייג ונטר פצצה: החברה שהקים, Celera, עומדת להשלים את המשימה בתוך שלוש שנים בלבד. הכרזה זו השליכה את שני הארגונים לתוך מירוץ מטורף שישנה את פני מדע הגנטיקה. 

One of the original Celera team that worked on the Human Genome Project, Gene Myers is now setting up the new Center for Systems Biology at the Max Planck Institute of Molecular Cell Biology and Genetics. However, unlike many others such centers, the main focus of this institute will not be genomics. Rather Myers is going for microscopy. “Genomics is only about 20% of it,” he says in today’s interview from his office in Dresden, Germany

Guest: Gene Myers , Founding Director, Systems Biology Center, Max Planck Institute Bio and Contact Info Listen (6:10) What have you been up to since the Celera days?

My guest today is Eric Wong. Wong established TCG on behalf of his family in 2003 as an asset management and financial advisory firm focused on investments with superior risk adjusted returns that are uncorrelated to major asset classes and advising family office and corporate clients. TCG's Celera division was formed in 2012 to consolidate and spin out the markets, technology, and business infrastructure of TCG. The topic is entrepreneur. In this episode of Trend Following Radio we discuss: How the rest of the world has a long way to go to understanding how China operates The niche that Wong's family office, TCG, occupies in the trading space Uncorrelated returns The advantages of working for a family office The entrepreneurial history of Wong's family Trend following data, data points, and the importance of data over a long period of time The Sharpe Ratio, and why the rest of the investing world has a problem with rejecting it The importance of pain as a measure Why Chinese investors are more driven by returns, and often agnostic to particular investment strategies Investor optimism "Nimbleness" to new ideas in Chinese culture Entrepreneurism in Asia and America Jump in! --- I'm MICHAEL COVEL, the host of TREND FOLLOWING RADIO, and I'm proud to have delivered 10+ million podcast listens since 2012. Investments, economics, psychology, politics, decision-making, human behavior, entrepreneurship and trend following are all passionately explored and debated on my show. To start? I'd like to give you a great piece of advice you can use in your life and trading journey… cut your losses! You will find much more about that philosophy here: https://www.trendfollowing.com/trend/ You can watch a free video here: https://www.trendfollowing.com/video/ Can't get enough of this episode? You can choose from my thousand plus episodes here: https://www.trendfollowing.com/podcast My social media platforms: Twitter: @covel Facebook: @trendfollowing LinkedIn: @covel Instagram: @mikecovel Hope you enjoy my never-ending podcast conversation!